id category authors creation_date issue published_in summary volume PMID:13679426 biolink:Article Chen M, Dong Y, Simard JM 2003-01-01 24 NCIT:C17998 Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain 23 PMID:10064839 biolink:Article Chou YC, Liao JF, Chang WY, Lin MF, Chen CF 1999-01-01 2 NCIT:C17998 Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan 821 PMID:21818695 biolink:Article Benet LZ, Broccatelli F, Oprea TI 2011-01-01 4 NLM:101223209 BDDCS applied to over 900 drugs 13 PMID:15546675 biolink:Article Contrera JF, Matthews EJ, Kruhlak NL, Benz RD 2004-01-01 3 NCIT:C17998 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose 40 PMID:26589308 biolink:Article Hosey CM, Chan R, Benet LZ 2016-01-01 1 NLM:101223209 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs 18 PMID:24306326 biolink:Article Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H 2014-01-01 4 NLM:8406521 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches 31 PMID:30115648 biolink:Article Lombardo F, Berellini G, Obach RS 2018-01-01 11 NCIT:C17998 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds 46 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761115Orig1s000MultidisciplineR.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf biolink:Publication 2020-01-01 PMID:21918175 biolink:Article Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS, Behshad E, Wynn R, Li Y, Boer J, Diamond S, He C, Xu M, Zhuo J, Yao W, Newton RC, Scherle PA 2011-01-01 22 NCIT:C17998 A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3 17 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213246Orig1s000MultidisciplineR.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf biolink:Publication 2020-01-01 PMID:31085175 biolink:Article Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikepalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates K, Janku F, Abdul Razak AR, Rosen O, Heinrich MC, Flynn DL 2019-01-01 5 NLM:101130617 Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants 35 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212155s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212123s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf biolink:Publication 2020-01-01 PMID:17585216 biolink:Article Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, Wiard RP, Feldman PL, Collins H, Waszczak BL, Tilbrook GS 2007-01-01 1 NLM:1300217 CNS 7056: a novel ultra-short-acting benzodiazepine 107 PMID:22547625 biolink:Article Nowicka-Sans B, Gong YF, McAuliffe B, Dicker I, Ho HT, Zhou N, Eggers B, Lin PF, Ray N, Wind-Rotolo M, Zhu L, Majumdar A, Stock D, Lataillade M, Hanna GJ, Matiskella JD, Ueda Y, Wang T, Kadow JF, Meanwell NA, Krystal M 2012-01-01 7 NCIT:C17998 In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068 56 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212576s000lbl.pdf biolink:Publication 2020-01-01 PMID:24520856 biolink:Article Ferraris D, Duvall B, Delahanty G, Mistry B, Alt J, Rojas C, Rowbottom C, Sanders K, Schuck E, Huang KC, Redkar S, Slusher BB, Tsukamoto T 2014-01-01 6 NCIT:C17998 Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase 57 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761163Orig1s000MultidisciplineR.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761163s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761158Orig1s000MultidisciplineR.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf biolink:Publication 2020-01-01 PMID:32936437 biolink:Article Markham A 2020-01-01 15 NCIT:C17998 Belantamab Mafodotin: First Approval 80 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210730s000lbl.pdf biolink:Publication 2020-01-01 PMID:23300227 biolink:Article DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD 2013-01-01 3 NCIT:C17998 A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine 344 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212154Orig1s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212154Orig1s000PharmR.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761149s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761149Orig1s000PharmR.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213433s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213227s000lbl.pdf biolink:Publication 2020-01-01 PMID:29668724 biolink:Article Rylova SN, Stoykow C, Del Pozzo L, Abiraj K, Tamma ML, Kiefer Y, Fani M, Maecke HR 2018-01-01 4 NCIT:C17998 The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft mod 13 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf biolink:Publication 2020-01-01 PMID:29657135 biolink:Article Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK 2018-01-01 7 NCIT:C17998 Precision targeted therapy with BLU-667 for RET-driven cancers 8 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf biolink:Publication 2020-01-01 PMID:32668216 biolink:Article Pruijssers AJ, George AS, Schafer A, Leist SR, Gralinksi LE, Dinnon KH 3rd, Yount BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR, Sheahan TP 2020-01-01 3 NCIT:C17998 Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice 32 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761156s000lbl.pdf biolink:Publication 2020-01-01 PMID:32053994 biolink:Article Petersen M, Gandhi PS, Buchardt J, Alanentalo T, Fels JJ, Johansen NL, Helding-Kvist P, Vad K, Thygesen P 2020-01-01 4 NCIT:C17998 Tissue distribution and receptor activation by somapacitan, a long acting growth hormone derivative 21 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf biolink:Publication 2020-01-01 PMID:10377218 biolink:Article Strickland CL, Weber PC, Windsor WT, Wu Z, Le HV, Albanese MM, Alvarez CS, Cesarz D, del Rosario J, Deskus J, Mallams AK, Njoroge FG, Piwinski JJ, Remiszewski S, Rossman RR, Taveras AG, Vibulbhan B, Doll RJ, Girijavallabhan VM, Ganguly AK 1999-01-01 12 NCIT:C17998 Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure−activity relationships 42 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793Orig1s000RPLlbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf biolink:Publication 2020-01-01 https://www.ema.europa.eu/en/documents/product-information/hepcludex-epar-product-information_en.pdf biolink:Publication 2020-01-01 PMID:33058042 biolink:Article Al-Salama ZT 2020-01-01 17 NCIT:C17998 Imlifidase: first approval 80 https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf biolink:Publication 2020-01-01 PMID:24006460 biolink:Article Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, Lepescheux L, Christophe T, Conrath K, Vandeghinste N, Vayssiere B, De Vos S, Fletcher S, Brys R, van't Klooster G, Feyen JH, Menet C 2013-01-01 7 NCIT:C17998 Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases 191 PMID:32852744 biolink:Article Markham A 2020-01-01 13 NCIT:C17998 Vadadustat: first approval 80 PMID:32880805 biolink:Article Dhillon S 2020-01-01 14 NCIT:C17998 Daprodustat: first approval 80 PMID:28928122 biolink:Article Ariazi JL, Duffy KJ, Adams DF, Fitch DM, Luo L, Pappalardi M, Biju M, DiFilippo EH, Shaw T, Wiggall K, Erickson-Miller C 2017-01-01 3 NCIT:C17998 Discovery and preclinical characterization of GSK1278863 (daprodustat), a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for anemia 363 PMID:31953125 biolink:Article Liclican A, Serafini L, Xing W, Czerwieniec G, Steiner B, Wang T, Brendza KM, Lutz JD, Keegan KS, Ray AS, Schultz BE, Sakowicz R, Feng JY 2020-01-01 4 NCIT:C17998 Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition 1864 PMID:32361823 biolink:Article Markham A 2020-01-01 8 NCIT:C17998 Tepotinib: first approval 80 PMID:23553846 biolink:Article Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Gradler U, Meyring M, Dorsch D, Jaehrling F, Pehl U, Stieber F, Schadt O, Blaukat A 2013-01-01 11 NCIT:C17998 EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors 19 PMID:31371478 biolink:Article Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, Chikamatsu N, Hagihara C, Hashiba M, Iwanaga T 2019-01-01 1 NCIT:C17998 Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor 371 PMID:33062187 biolink:Article Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T 2020-01-01 10 NLM:101521073 Discovery of dotinurad (FYU-981), a new phenol derivative with highly potent uric acid lowering activity 11 PMID:25387665 biolink:Article Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M 2015-01-01 1 NCIT:C17998 Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo 64 PMID:31301309 biolink:Article Fukui K, Shinozaki Y, Kobayashi H, Deai K, Yoshiuchi H, Matsui T, Matsuo A, Matsushita M, Tanaka T, Nangaku M 2019-01-01 859 NCIT:C17998 JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor 15 PMID:33320297 biolink:Article Markham A 2020-01-01 NCIT:C17998 Enarodustat: first approval PMID:33236266 biolink:Article Paik J 2020-01-01 18 NCIT:C17998 Sofpironium Bromide: first approval 80 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf biolink:Publication 2020-01-01 PMID:29619657 biolink:Article Sanchez-Crespo A, Jussing E, Björklund AC, Pokrovskaja Tamm K 2018-01-01 1 NCIT:C17998 Hallmarks in prostate cancer imaging with Ga68-PSMA-11-PET/CT with reference to detection limits and quantitative properties 8 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf biolink:Publication 2020-01-01 PMID:30937733 biolink:Article Markham A 2019-01-01 6 NCIT:C17998 Relugolix: first global approval 79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761172s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761171Orig1s000MultidisciplineR.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761169s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213973Orig1s000MultidisciplineR.pdf biolink:Publication 2020-01-01 PMID:20605905 biolink:Article Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K, Evans K, Sims GP, Pfarr DS, Bowen MA, Dall'Acqua W, Shlomchik M, Tedder TF, Kiener P, Jallal B, Wu H, Coyle AJ 2010-01-01 1 NCIT:C17998 B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody 335 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213433Orig1s000MultidisciplineR.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213721Orig1s000MultidisciplineR.pdf biolink:Publication 2020-01-01 PMID:31132753 biolink:Article Bailly C 2019-01-01 NCIT:C17998 Cepharanthine: An update of its mode of action, pharmacological properties and medical applications 62 PMID:32149769 biolink:Article Fan HH, Wang LQ, Liu WL, An XP, Liu ZD, He XQ, Song LH, Tong YG 2020-01-01 NCIT:C17998 Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model DOI:10.26434/chemrxiv.12039888.v1 biolink:Article Xu Z, Yao H, Shen J, Wu N, Xu Y, Lu X 2020-01-01 NLM:101720906 Nelfinavir is active against SARS-CoV-2 in Vero E6 cells PMID:32251768 biolink:Article Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM 2020-01-01 NCIT:C17998 The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro DOI:10.1101/2020.03.20.999730 biolink:Article Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S 2020-01-01 NLM:101680187 Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs DOI:10.1101/2020.04.03.023846 biolink:Article Touret F, Gilles M, Barral K, Nougairede A, Decroly E, de Lamballerie X, Coutard B 2020-01-01 NLM:101680187 In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication PMID:32194981 biolink:Article Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M 2020-01-01 16 NCIT:C17998 Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro 6 PMID:32251767 biolink:Article Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PP, Huang X, Peiris M, Yen HL 2020-01-01 NCIT:C17998 Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro 178 PMID:32020029 biolink:Article Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G 2020-01-01 3 NCIT:C17998 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro 30 DOI:10.1101/2020.03.11.987016 biolink:Article Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, Shimojima M, Fukushi S 2020-01-01 NLM:101680187 The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 DOI:10.1101/2020.03.23.004580 biolink:Article Li Z, Li X, Huang YY, Wu Y, Zhou L, Liu R, Wu D, Zhang L, Liu H, Xu X, Zhang Y, Cui J, Wang X, Luo HB 2020-01-01 NLM:101680187 FEP-based screening prompts drug repositioning against COVID-19 DOI:10.1101/2020.02.05.935387 biolink:Article Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, Zhang H 2020-01-01 NLM:101680187 Teicoplanin potently blocks the cell entry of 2019-nCoV PMID:32253226 biolink:Article Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schafer A, Dinnon KH, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS 2020-01-01 NCIT:C17998 An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice DOI:10.1101/2020.03.11.986836 biolink:Article Ge Y, Tian T, Huang S, Wan F, Li J, Li S, Yang H, Hong L, Wu N, Yuan E, Cheng L, Lei Y, Shu H, Feng X, Jiang Z, Chi Y, Guo X, Cui L, Xiao L, Li Z, Yang C, Miao Z, Tang H, Chen L, Zeng H, Zhao D, Zhu F, Shen X, Zeng J 2020-01-01 NLM:101680187 A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf biolink:Publication 2020-01-01 PMID:29093181 biolink:Article Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schöffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C 2017-01-01 414 NCIT:C17998 A precision therapy against cancers driven by KIT/PDGFRA mutations 9 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211723s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf biolink:Publication 2020-01-01 PMID:23153230 biolink:Article Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L, Kostich W, Lentz KA, Santone KS, Schartman R, Browning M, Tong G, Houston JG, Dubowchik GM, Macor JE 2012-01-01 23 NCIT:C17998 Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine 55 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf biolink:Publication 2020-01-01 PMID:27892461 biolink:Article Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND 2016-01-01 NLM:101528555 Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis 7 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf biolink:Publication 2020-01-01 PMID:26990079 biolink:Article Scott FL, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, Desale HG, Timony GA, Martinborough E, Rosen H, Roberts E, Boehm MF, Peach RJ 2016-01-01 11 NCIT:C17998 Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity 173 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf biolink:Publication 2020-01-01 PMID:32141023 biolink:Article Duggan S 2020-01-01 5 NCIT:C17998 Osilodrostat: First Approval 80 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761113s000lbl.pdf biolink:Publication 2020-01-01 PMID:24987056 biolink:Article Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallee F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blanc V 2014-01-01 17 NCIT:C17998 SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies 20 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761119Orig1s000OtherR.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761143s000lbl.pdf biolink:Publication 2020-01-01 PMID:20847162 biolink:Article Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Franssen GM, Versleijen-Jonkers YM, Oyen WJ, van der Graaf WT, Boerman OC 2010-01-01 10 NCIT:C17998 ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model 51 PMID:17332304 biolink:Article Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E 2007-01-01 5 NCIT:C17998 Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor 13 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf biolink:Publication 2020-01-01 PMID:32241871 biolink:Article Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, Forero-Torres A, Peterson S 2020-01-01 4 NCIT:C17998 Preclinical activity of HER2-Selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models 19 PMID:32315352 biolink:Article Liu PCC, Koblish H, Wu L, Bowman K, Diamond S, DiMatteo D, Zhang Y, Hansbury M, Rupar M, Wen X, Collier P, Feldman P, Klabe R, Burke KA, Soloviev M, Gardiner C, He X, Volgina A, Covington M, Ruggeri B, Wynn R, Burn TC, Scherle P, Yeleswaram S, Yao W, Huber R, Hollis G 2020-01-01 4 NCIT:C17998 INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models 15 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf biolink:Publication 2020-01-01 PMID:27926532 biolink:Article He JX, Wang M, Huan XJ, Chen CH, Song SS, Wang YQ, Liao XM, Tan C, He Q, Tong LJ, Wang YT, Li XH, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Gao ZW, Chen XY, Xiong B, Lu XL, Ding J, Yang CH, Miao ZH 2017-01-01 3 NLM:101532965 Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution 8 PMID:26934220 biolink:Article Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR5, Flint M, McMullan LK, Chen SS, Fearns R5, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S 2016-01-01 7594 NLM:0410462 Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys 531 DOI:10.1016/S0016-5085(10)61017-7 biolink:Article Gillberg, Per-Göran; Dahlström, Mikael; AU - Starke, Ingemar; Östlund-Lindqvist, Ann-Margret 2010-01-01 5 NCIT:C17998 S1301 The IBAT Inhibition by A3309 - A Potential Mechanism for the Treatment of Constipation 138 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208700s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205598s000lbl.pdf biolink:Publication 2017-01-01 PMID:12240910 biolink:Article Broglio F, Boutignon F, Benso A, Gottero C, Prodam F, Arvat E, Ghè C, Catapano F, Torsello A, Locatelli V, Muccioli G, Boeglin D, Guerlavais V, Fehrentz JA, Martinez J, Ghigo E, Deghenghi R 2002-01-01 8 NCIT:C17998 EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man. 25 PMID:24002361 biolink:Article Butler MS, Blaskovich MA, Cooper MA 2013-01-01 10 NCIT:C17998 Antibiotics in the clinical pipeline in 2013 66 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761092s000lbl.pdf biolink:Publication 2018-01-01 PMID:27645238 biolink:Article Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, Tsai L, Bam RA, Stepan G, Stray KM, Niedziela-Majka A, Yant SR, Yu H, Kukolj G, Cihlar T, Lazerwith SE, White KL, Jin H 2016-01-01 12 NCIT:C17998 Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. 60 PMID:16135657 biolink:Article Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I 2005-01-01 12 NCIT:C17998 Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. 33 https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021462lbl.pdf biolink:Publication 2004-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065s001lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209299lbl.pdf biolink:Publication 2018-01-01 PMID:16946104 biolink:Article Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. 2006-01-01 3 NCIT:C17998 R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. 319 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761068s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210493s000lbl.pdf/drugsatfda_docs/label/2014/125477s007lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf biolink:Publication 2018-01-01 PMID:19183407 biolink:Article Fukushima-Shintani M, Suzuki K, Iwatsuki Y, Abe M, Sugasawa K, Hirayama F, Kawasaki T, Nakahata T 2009-01-01 4 NCIT:C17998 AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. 82 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf biolink:Publication 2018-01-01 PMID:26559125 biolink:Article Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C 2016-01-01 1 NCIT:C17998 Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. 356 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208627s000lbl.pdf biolink:Publication 2018-01-01 PMID:29670690 biolink:Article Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G, Cai Z, Zhou D, Cui D, Chen P, Straley K, Tobin E, Wang F, David MD, Penard-Lacronique V, Quivoron C, Saada V, de Botton S, Gross S, Dang L, Yang H, Utley L, Chen Y, Kim H, Jin S, Gu Z, Yao G, Luo Z, Lv X, Fang C, Yan L, Olaharski A, Silverman L, Biller S, Su SM, Yen K. 2018-01-01 4 NLM:101521073 Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers 9 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf biolink:Publication 2018-01-01 PMID:19006286 biolink:Article Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M, Chen Y, Tucci FC, Rowbottom M, Pontillo J, Zhu YF, Wade W, Saunders J, Bozigian H, Struthers RS 2008-01-01 23 NCIT:C17998 Discovery of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor 51 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210450s000lbl.pdf biolink:Publication 2018-01-01 PMID:29274361 biolink:Article Yoshida H, Yamada H, Nogami W, Dohi K, Kurino-Yamada T, Sugiyama K, Takahashi K, Gahara Y, Kitaura M, Hasegawa M, Oshima I, Kuwabara K. 2018-01-01 NCIT:C17998 Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl 59 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf biolink:Publication 2018-01-01 PMID:24211136 biolink:Article Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li LS, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL 2013-01-01 11 NCIT:C17998 PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. 20 PMID:30506139 biolink:Article Shirley M 2018-01-01 18 NCIT:C17998 Dacomitinib: First Global Approval. 78 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf biolink:Publication 2018-01-01 PMID:26652717 biolink:Article Wang B, Chu D, Feng Y, Shen Y, Aoyagi-Scharber M, Post LE 2016-01-01 1 NCIT:C17998 Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. 59 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761102s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf biolink:Publication 2018-01-01 PMID:26144315 biolink:Article Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, Timofeevski S, Katayama R, Dinh DM, Lam H, Lam JL, Yamazaki S, Hu W, Patel B, Bezwada D, Frias RL, Lifshits E, Mahmood S, Gainor JF, Affolter T, Lappin PB, Gukasyan H, Lee N, Deng S, Jain RK, Johnson TW, Shaw AT, Fantin VR, Smeal T. 2015-01-01 1 NLM:101130617 PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. 28 PMID:27401242 biolink:Article Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, Andre F, Soria JC, Friboulet L 2016-01-01 24 NCIT:C17998 Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. 22 PMID:25733882 biolink:Article Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, McTigue M, Deng YL, Liu W, Brooun A, Timofeevski S, McDonnell SR, Jiang P, Falk MD, Lappin PB, Affolter T, Nichols T, Hu W, Lam J, Johnson TW, Smeal T, Charest A, Fantin VR 2015-01-01 11 NCIT:C17998 PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. 112 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf biolink:Publication 2018-01-01 PMID:29736245 biolink:Article Hegde SS, Pulido-Rios MT, Luttmann MA, Foley JJ, Hunsberger GE, Steinfeld T, Lee T, Ji Y, Mammen MM, Jasper JR 2018-01-01 3 NCIT:C17998 Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. 6 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf biolink:Publication 2018-01-01 PMID:24900436 biolink:Article Munchhof MJ, Li Q, Shavnya A, Borzillo GV, Boyden TL, Jones CS, LaGreca SD, Martinez-Alsina L, Patel N, Pelletier K, Reiter LA, Robbins MD, Tkalcevic GT 2011-01-01 2 NLM:101521073 Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened. 3 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf biolink:Publication 2018-01-01 PMID:21138586 biolink:Article Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Mantyh WG, Bloom AP, Kuskowski MA, Mantyh PW. 2010-01-01 1 NCIT:C17998 Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain. 6 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf biolink:Publication 2018-01-01 PMID:27908881 biolink:Article Lee LY, Hernandez D, Rajkhowa T, Smith SC, Raman JR, Nguyen B, Small D, Levis M 2017-01-01 2 NLM:7603509 Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor 129 PMID:29724589 biolink:Article Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, Kuroda M, Hisada Y, Yanagida T, Yoneda H, Tsukumo Y, Tokunaga S, Kawata T, Ohashi R, Fukuda H, Kojima K, Kannami A, Kifuji T, Sato N, Idei A, Iguchi T, Sakairi T, Moritani Y. 2018-01-01 11 NCIT:C17998 Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. 28 PMID:30267321 biolink:Article Syed YY 2018-01-01 15 NCIT:C17998 Lanadelumab: First Global Approval. 78 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf biolink:Publication 2018-01-01 PMID:30411311 biolink:Article Keam SJ 2018-01-01 17 NCIT:C17998 Vibegron: First Global Approval. 78 PMID:30465134 biolink:Article Duggan S 2018-01-01 18 NCIT:C17998 Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval. 78 PMID:30298461 biolink:Article Duggan S 2018-01-01 15 NCIT:C17998 Caplacizumab: First Global Approval. 78 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761104s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761089s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf biolink:Publication 2018-01-01 PMID:28265006 biolink:Article Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al 2017-01-01 5 NCIT:C17998 Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice. 16 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761107s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761108s000lbl.pdf biolink:Publication 2018-01-01 PMID:29649283 biolink:Article Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, Bouchard K, Andrien B, Marozsan A, Wang Y et al 2018-01-01 4 NCIT:C17998 Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action 13 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761116s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf biolink:Publication 2018-01-01 PMID:25531770 biolink:Article Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS 2014-01-01 12 NCIT:C17998 Characterization of structure and function of ZS-9, a K+ selective ion trap 9 PMID:25651699 biolink:Article Verma M, Pathak M, Shahab M, Singh K, Mitra K, Misra-Bhattacharya S 2014-01-01 6 NCIT:C17998 Moxidectin causes adult worm mortality of human lymphatic filarial parasite Brugia malayi in rodent models 61 PMID:23108553 biolink:Article Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS 2012-01-01 1607 NLM:7503623 Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders 367 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303Orig1s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210795s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211172lbl.pdf biolink:Publication 2018-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211371Orig1s000MultidisciplineR.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf biolink:Publication 2019-01-01 PMID:31144287 biolink:Article Al-Salama ZT 2019-01-01 9 NCIT:C17998 Siponimod: First global approval 79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf biolink:Publication 2019-01-01 PMID:31161538 biolink:Article Markham A 2019-01-01 9 NCIT:C17998 Erdafitinib: First global approval 79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf biolink:Publication 2019-01-01 PMID:31256368 biolink:Article Markham A 2019-01-01 11 NCIT:C17998 Alpelisib: First global approval 79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212306s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf biolink:Publication 2019-01-01 PMID:26137992 biolink:Article Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykanen PS, Tormakangas OP, Palvimo JJ, Kallio PJ 2015-01-01 NLM:101563288 Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies 5 https://www.ema.europa.eu/en/documents/assessment-report/waylivra-epar-public-assessment-report_en.pdf biolink:Publication 2019-01-01 PMID:31301033 biolink:Article Paik J, Duggan S 2019-01-01 12 NCIT:C17998 Volanesorsen: First global approval 79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf biolink:Publication 2019-01-01 PMID:25905918 biolink:Article Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, He Y, Raymond EL, Ahlberg J, Frego LE, Amodeo LM, Catron KM, Presky DH, Hanke JH 2015-01-01 4 NCIT:C17998 Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody 7 https://www.ema.europa.eu/en/documents/product-information/besremi-epar-product-information_en.pdf biolink:Publication 2019-01-01 https://www.ema.europa.eu/en/documents/product-information/zynquista-epar-product-information_en.pdf biolink:Publication 2019-01-01 PMID:22739142 biolink:Article Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, Mseeh F, Rawlins DB, Goodwin NC, Mabon R, Harrison BA, Wilson A, Sands A, Powell DR 2012-01-01 2 NCIT:C17998 LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial 92 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761079s000lbl.pdf biolink:Publication 2019-01-01 PMID:19754199 biolink:Article Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, Gunawardane RN, Cramer MD, Gardner MF, James J, Zarrinkar PP, Patel HK, Bhagwat SS 2009-01-01 23 NCIT:C17998 Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor 52 PMID:19654408 biolink:Article Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS 2009-01-01 14 NLM:7603509 AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) 114 https://clinicaltrials.gov/ProvidedDocs/61/NCT02215161/Prot_SAP_000.pdf biolink:Publication 2018-01-01 Phase II single agent study of selinexor (KPT-330) in patients with metastatic castration-resistant prostate cancer (MCRPC) and prior therapy with abiraterone and/or enzalutamide PMID:23183107 biolink:Article Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, Rosenberg A, Tran T, Xiao Y, Zarate CA, Wainer IW 2013-01-01 1-3 NCIT:C17998 Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors 698 https://www.fda.gov/media/113279/download biolink:Publication 2018-01-01 PMID:12851303 biolink:Article Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY 2003-01-01 1 NCIT:C17998 PT-141: a melanocortin agonist for the treatment of sexual dysfunction 994 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761085s000lbl.pdf biolink:Publication 2019-01-01 PMID:31383664 biolink:Article Tooke CL, Hinchliffe P, Lang PA, Mulholland AJ, Brem J, Schofield CJ, Spencer J 2019-01-01 10 NCIT:C17998 Molecular Basis of Class A beta-Lactamase Inhibition by Relebactam 23 PMID:26222558 biolink:Article Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G 2015-01-01 5 NLM:9801742 Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor 373 PMID:24170767 biolink:Article Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, Fracasso PR, Wilkie DP, Hentemann M, Wilhelm SM, Scott WJ, Mumberg D, Ziegelbauer K 2013-01-01 11 NCIT:C17998 BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. 12 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf biolink:Publication 2017-01-01 PMID:21293470 biolink:Article Ji XC, Zhao WH, Cao DX, Shi QQ, Wang XL 2011-01-01 2 NLM:100956087 Novel neuroprotectant chiral 3-n-butylphthalide inhibits tandem-pore-domain potassium channel TREK-1. 32 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf biolink:Publication 2017-01-01 PMID:28949138 biolink:Article Lynagh T, Romero-Rojo JL, Lund C, Pless SA 2017-01-01 NCIT:C17998 Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf biolink:Publication 2017-01-01 PMID:24919854 biolink:Article Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A 2014-01-01 5 NCIT:C17998 Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. 32 PMID:21396362 biolink:Article Krauss AH, Impagnatiello F, Toris CB, Gale DC, Prasanna G, Borghi V, Chiroli V, Chong WK, Carreiro ST, Ongini E 2011-01-01 3 NCIT:C17998 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. 93 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209939Orig1s000,209940Orig1s000lbl.pdf biolink:Publication 2017-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf biolink:Publication 2017-01-01 PMID:26308095 biolink:Article Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T 2015-01-01 18 NCIT:C17998 Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. 58 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf biolink:Publication 2017-01-01 PMID:27072905 biolink:Article Sturdivant JM, Royalty SM, Lin CW, Moore LA, Yingling JD, Laethem CL, Sherman B, Heintzelman GR, Kopczynski CC, deLong MA 2016-01-01 10 NCIT:C17998 Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. 26 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf biolink:Publication 2017-01-01 PMID:26641137 biolink:Article Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR 2016-01-01 4 NLM:9801742 Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. 374 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf biolink:Publication 2017-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004131/WC500239033.pdf biolink:Publication 2017-01-01 PMID:16982756 biolink:Article Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T 2006-01-01 18 NCIT:C17998 KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. 66 PMID:14623894 biolink:Article Pham V, Wade JD, Purdue BW, Sexton PM 2004-01-01 8 NLM:2985121R Spatial proximity between a photolabile residue in position 19 of salmon calcitonin and the amino terminus of the human calcitonin receptor. 279 PMID:10385705 biolink:Article Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, Main MJ, Foord SM, Sexton PM 1999-01-01 1 NCIT:C17998 Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. 56 PMID:15692146 biolink:Article Hay DL, Christopoulos G, Christopoulos A, Poyner DR, Sexton PM 2005-01-01 5 NCIT:C17998 Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. 67 PMID:21449606 biolink:Article Mascitti V, Maurer TS, Robinson RP, Bian J, Boustany-Kari CM, Brandt T, Collman BM, Kalgutkar AS, Klenotic MK, Leininger MT, Lowe A, Maguire RJ, Masterson VM, Miao Z, Mukaiyama E, Patel JD, Pettersen JC, Préville C, Samas B, She L, Sobol Z, Steppan CM, Stevens BD, Thuma BA, Tugnait M, Zeng D, Zhu T 2011-01-01 8 NCIT:C17998 Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. 54 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf biolink:Publication 2017-01-01 PMID:10193788 biolink:Article Vanderheyden PM, Fierens FL, De Backer JP, Fraeyman N, Vauquelin G 1999-01-01 4 NCIT:C17998 Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors. 126 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209360s000lbl.pdf biolink:Publication 2017-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209360s000lbl.pdf biolink:Publication 2018-01-01 PMID:22266222 biolink:Article Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH 2012-01-01 6 NCIT:C17998 ARN-509: a novel antiandrogen for prostate cancer treatment. 72 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210951s000lbl.pdf biolink:Publication 2018-01-01 PMID:22711801 biolink:Article Gregori-Puigjané E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, Marnett L, Roth BL, Shoichet BK 2012-01-01 28 NCIT:C17998 Identifying mechanism-of-action targets for drugs and probes. 109 PMID:9628722 biolink:Article Miles RW, Tyler PC, Furneaux RH, Bagdassarian CK, Schramm VL 1998-01-01 24 NCIT:C17998 One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. 37 PMID:17897085 biolink:Article Korycka A, Błoński JZ, Robak T 2007-01-01 9 NCIT:C17998 Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application. 7 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997Orig1Orig2s000lbl.pdf biolink:Publication 2017-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf biolink:Publication 2017-01-01 PMID:26562265 biolink:Article Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ 2016-01-01 1 NCIT:C17998 Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. 157 PMID:27780853 biolink:Article Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, Ning Y, Wardwell SD, Miller D, Song Y, Eichinger L, Moran L, Huang WS, Liu S, Zou D, Wang Y, Mohemmad Q, Jang HG, Ye E, Narasimhan N, Wang F, Miret J, Zhu X, Clackson T, Dalgarno D, Shakespeare WC, Rivera VM 2016-01-01 22 NCIT:C17998 The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. 22 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf biolink:Publication 2017-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761052lbl.pdf biolink:Publication 2017-01-01 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7aa0bae-255b-4792-a963-6606370a175f biolink:Publication 2009-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf biolink:Publication 2012-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761037s000lbl.pdf biolink:Publication 2017-01-01 PMID:14761182 biolink:Article Shin SS, Byun Y, Lim KM, Choi JK, Lee KW, Moh JH, Kim JK, Jeong YS, Kim JY, Choi YH, Koh HJ, Park YH, Oh YI, Noh MS, Chung S 2004-01-01 4 NCIT:C17998 In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. 47 PMID:21570283 biolink:Article Kim HJ, Kwak WY, Min JP, Lee JY, Yoon TH, Kim HD, Shin CY, Kim MK, Choi SH, Kim HS, Yang EK, Cheong YH, Chae YN, Park KJ, Jang JM, Choi SJ, Son MH, Kim SH, Yoo M, Lee BJ 2011-01-01 12 NCIT:C17998 Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. 21 PMID:21093089 biolink:Article Cho JM, Jang HW, Cheon H, Jeong YT, Kim DH, Lim YM, Choi SH, Yang EK, Shin CY, Son MH, Kim SH, Kim HJ, Lee MS 2011-01-01 1 NCIT:C17998 A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis. 91 PMID:22278334 biolink:Article Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, Fitzgerald GA 2012-01-01 6 NCIT:C17998 Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. 91 PMID:19297154 biolink:Article Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T, Fan J, Wu Y, Li W, Woolfrey J, Sinha U, Wong PW, Edwards ST, Arfsten AE, Clizbe LA, Kanter J, Pandey A, Park G, Hutchaleelaha A, Lambing JL, Hollenbach SJ, Scarborough RM, Zhu BY 2009-01-01 8 NCIT:C17998 Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. 19 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf biolink:Publication 2017-01-01 PMID:1446593 biolink:Article LaPolt PS, Nishimori K, Fares FA, Perlas E, Boime I, Hsueh AJ 1992-01-01 6 NCIT:C17998 Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides. 131 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf biolink:Publication 2017-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004119/WC500231261.pdf biolink:Publication 2017-01-01 PMID:17553678 biolink:Article Yamazaki Y, Abe K, Toma T, Nishikawa M, Ozawa H, Okuda A, Araki T, Oda S, Inoue K, Shibuya K, Staels B, Fruchart JC 2007-01-01 16 NCIT:C17998 Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. 17 DOI: biolink:Article Bai AP, Guo ZR, Hu WH, Shen F, Cheng GF. 2001-01-01 9 NCIT:C17998 Design, synthesis and in vitro evaluation of a new class of novel cyclooxygenase-2 inhibitors: 3,4-diaryl-3-pyrrolin-2-ones. 12 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf biolink:Publication 2017-01-01 PMID:28193778 biolink:Article Yen K, Travins J, Wang F, David MD, Artin E, Straley K, Padyana A, Gross S, DeLaBarre B, Tobin E, Chen Y, Nagaraja R, Choe S, Jin L, Konteatis Z, Cianchetta G, Saunders JO, Salituro FG, Quivoron C, Opolon P, Bawa O, Saada V, Paci A, Broutin S, Bernard OA, de Botton S, Marteyn BS, Pilichowska M, Xu Y, Fang C, Jiang F, Wei W, Jin S, Silverman L, Liu W, Yang H, Dang L, Dorsch M, Penard-Lacronique V, Biller SA, Su SM 2017-01-01 5 NCIT:C17998 AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. 7 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf biolink:Publication 2017-01-01 PMID:15715478 biolink:Article Tsou HR, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, Michalak RS, Nilakantan R, Discafani C, Golas J, Rabindran SK, Shen R, Shi X, Wang YF, Upeslacis J, Wissner A 2005-01-01 4 NCIT:C17998 Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. 48 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf biolink:Publication 2017-01-01 PMID:15210067 biolink:Article Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF 2004-01-01 7 NLM:100956087 Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. 25 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004209/WC500232105.pdf biolink:Publication 2017-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf biolink:Publication 2016-01-01 DOI:10.1021/acs.jmedchem.6b00990 biolink:Article Thorsell, Ann-Gerd and Ekblad, Torun and Karlberg, Tobias and Löw, Mirjam and Pinto, Ana Filipa and Tresaugues, Lionel and Moche, Martin and Cohen, Michael S. and Schüler, Herwig 2016-01-01 NCIT:C17998 Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors PMID:20188549 biolink:Article Zhang YK, Plattner JJ, Akama T, Baker SJ, Hernandez VS, Sanders V, Freund Y, Kimura R, Bu W, Hold KM, Lu XS 2010-01-01 7 NCIT:C17998 Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application. 20 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207695s000lbl.pdf biolink:Publication 2016-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125293s085lbl.pdf biolink:Publication 2016-01-01 PMID:20363976 biolink:Article Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K 2010-01-01 9 NCIT:C17998 Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. 184 PMID:22959248 biolink:Article Hu S, Xie G, Zhang DX, Davis C, Long W, Hu Y, Wang F, Kang X, Tan F, Ding L, Wang Y 2012-01-01 19 NCIT:C17998 Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. 22 PMID:22088449 biolink:Article Wang HP, Zhang L, Wang YX, Tan FL, Xia Y, Ren GJ, Hu P, Jiang J, Wang MZ, Xiao Y 2011-01-01 13 NCIT:C17998 Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. 124 PMID:27357069 biolink:Article Kim ES 2016-01-01 11 NCIT:C17998 Olmutinib: First Global Approval. 76 http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208745lbl.pdf biolink:Publication 2017-01-01 PMID:26558155 biolink:Article Shailubhai K, Palejwala V, Arjunan KP, Saykhedkar S, Nefsky B, Foss JA, Comiskey S, Jacob GS, Plevy SE 2015-01-01 4 NCIT:C17998 Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. 6 PMID:24900196 biolink:Article Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, Strickley RG, Tsai LK, Stray KM, Wang Y, Rhodes GR, Desai MC 2010-01-01 5 NLM:101521073 Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer. 1 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203094s005lbl.pdf biolink:Publication 2016-01-01 PMID:25676420 biolink:Article Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, O'Hare T 2015-01-01 9 NLM:8704895 Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. 29 PMID:21443688 biolink:Article Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J, Lou L 2011-01-01 7 NCIT:C17998 YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. 102 PMID:28041831 biolink:Article Goldberg DR, De Lombaert S, Aiello R, Bourassa P, Barucci N, Zhang Q, Paralkar V, Stein AJ, Holt M, Valentine J, Zavadoski W 2017-01-01 3 NCIT:C17998 Optimization of spirocyclic proline tryptophan hydroxylase-1 inhibitors. 27 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125359s088lbl.pdf biolink:Publication 2016-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208794s000lbl.pdf biolink:Publication 2017-01-01 PMID:11314603 biolink:Article Nagatomo T, Hosohata Y, Ohnuki T, Nakamura T, Hattori K, Suzuki J, Ishiguro M 2001-01-01 1 NCIT:C17998 Bopindolol: pharmacological basis and clinical implications. 19 PMID:12152654 biolink:Article Gils A, Stassen JM, Nar H, Kley JT, Wienen W, Ries UJ, Declerck PJ 2002-01-01 1 NCIT:C17998 Characterization and comparative evaluation of a novel PAI-1 inhibitor. 88 http://www.medicines.org.uk/emc/medicine/1073 biolink:Publication 2017-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004085/WC500223723.pdf biolink:Publication 2017-01-01 PMID:27144355 biolink:Article Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD 2016-01-01 7604 NLM:0410462 NMDAR inhibition-independent antidepressant actions of ketamine metabolites. 533 http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf biolink:Publication 2017-01-01 PMID:25941111 biolink:Article VanArsdale T, Boshoff C, Arndt KT, Abraham RT 2015-01-01 13 NCIT:C17998 Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. 21 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208854s000lbl.pdf biolink:Publication 2017-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf biolink:Publication 2017-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf biolink:Publication 2017-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf biolink:Publication 2017-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf biolink:Publication 2017-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf biolink:Publication 2017-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf biolink:Publication 2017-01-01 PMID:22455412 biolink:Article Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S 2012-01-01 13 NLM:9801742 Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. 366 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003995/WC500217100.pdf biolink:Publication 2016-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761046s000lbl.pdf biolink:Publication 2016-01-01 PMID:9537821 biolink:Article Tatsumi M, Groshan K, Blakely RD, Richelson E 1997-01-01 2-3 NCIT:C17998 Pharmacological profile of antidepressants and related compounds at human monoamine transporters. 340 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761038lbl.pdf biolink:Publication 2016-01-01 PMID:24900456 biolink:Article Zhong M, Gadek TR, Bui M, Shen W, Burnier J, Barr KJ, Hanan EJ, Oslob JD, Yu CH, Zhu J, Arkin MR, Evanchik MJ, Flanagan WM, Hoch U, Hyde J, Prabhu S, Silverman JA, Wright J 2012-01-01 3 NLM:101521073 Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. 3 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208073s000lbl.pdf biolink:Publication 2016-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208524s000lbl.pdf biolink:Publication 2016-01-01 PMID:23301156 biolink:Article Realini N, Solorzano C, Pagliuca C, Pizzirani D, Armirotti A, Luciani R, Costi MP, Bandiera T, Piomelli D 2013-01-01 NLM:101563288 Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. 3 PMID:24113750 biolink:Article MacKenzie AE, Caltabiano G, Kent TC, Jenkins L, McCallum JE, Hudson BD, Nicklin SA, Fawcett L, Markwick R, Charlton SJ, Milligan G 2014-01-01 1 NCIT:C17998 The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. 85 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000253/WC500040495.pdf biolink:Publication 2016-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125499s009lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103628s5258lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103471s5188lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103172s5203lbl.pdf biolink:Publication 2015-01-01 PMID:16469866 biolink:Article Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE 2006-01-01 2 NCIT:C17998 Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. 317 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf biolink:Publication 2016-01-01 PMID:24847974 biolink:Article Lanier M, Ambrus G, Cole DC, Davenport R, Ellery J, Fosbeary R, Jennings AJ, Kadotani A, Kamada Y, Kamran R, Matsumoto S, Mizukami A, Okubo S, Okada K, Saikatendu K, Walsh L, Wu H, Hixon MS 2014-01-01 12 NCIT:C17998 A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT). 57 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034s000lbl.pdf biolink:Publication 2016-01-01 PMID:9713295 biolink:Article Denis L, Debruyne F, De Porre P, Bruynseels J 1998-01-01 4 NCIT:C17998 Early clinical experience with liarozole (Liazal) in patients with progressive prostate cancer. 34 PMID:21762037 biolink:Article Antoniu SA 2011-01-01 11 NCIT:C17998 Terguride for pulmonary arterial hypertension. 15 PMID:15627429 biolink:Article Thierry C, Boeynaems JM, Paolo M 2005-01-01 3 NCIT:C17998 Actions of tilidine and nortilidine on cloned opioid receptors. 506 PMID:11523024 biolink:Article Karp JE 2001-01-01 3 Suppl 7 NLM:0404514 Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. 38 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004059/WC500208434.pdf biolink:Publication 2016-01-01 PMID:12166927 biolink:Article Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM 2002-01-01 17 NCIT:C17998 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. 45 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf biolink:Publication 2016-01-01 PMID:8736619 biolink:Article Patel SS, Wilde MI 1996-01-01 6 NCIT:C17998 Ebrotidine. 51 PMID:7693433 biolink:Article Goa KL, Brogden RN 1993-01-01 3 NCIT:C17998 Propiram. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use as an analgesic. 46 PMID:6141283 biolink:Article Spiegel K, Pasternak GW 1984-01-01 2 NCIT:C17998 Meptazinol: a novel Mu-1 selective opioid analgesic. 228 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103951s5363lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103964s5264lbl.pdf biolink:Publication 2015-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000116/WC500024979.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103949s5299lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125164s071s072s073lbl.pdf biolink:Publication 2016-01-01 PMID:10776839 biolink:Article Dunn CJ, Goa KL 2000-01-01 3 NCIT:C17998 Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. 59 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000872/WC500054377.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022081s033lbl.pdf biolink:Publication 2015-01-01 PMID:9875499 biolink:Article Lee JH, Lee JM, Kim JK, Ahn SK, Lee SJ, Kim MY, Jew SS, Park JG, Hong CI 1998-01-01 5 NCIT:C17998 Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. 21 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf biolink:Publication 2016-01-01 PMID:2853885 biolink:Article Scherman D, Hamon M, Gozlan H, Henry JP, Lesage A, Masson M, Rumigny JF 1988-01-01 6 NCIT:C17998 Molecular pharmacology of niaprazine. 12 PMID:23291630 biolink:Article Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW 2013-01-01 2 NLM:9502015 ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. 19 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf biolink:Publication 2016-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103532s5175lbl.pdf biolink:Publication 2014-01-01 PMID:20040696 biolink:Article Gish EC, Miller JL, Honey BL, Johnson PN 2010-01-01 2 NCIT:C17998 Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. 44 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103411s5180lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208261Orig1s000lbl.pdf biolink:Publication 2016-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2011/05/WC500106736.pdf biolink:Publication 2013-01-01 PMID:12487507 biolink:Article Ishide T 2002-01-01 7 NCIT:C17998 Denopamine, a selective beta1-receptor agonist and a new coronary vasodilator. 18 PMID:7726994 biolink:Article Wouters W, Snoeck E, De Coster R 1994-01-01 1 NCIT:C17998 Vorozole, a specific non-steroidal aromatase inhibitor. 30 http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21396_prempro_lbl.pdf biolink:Publication 2003-01-01 PMID:2154989 biolink:Article Morii M, Takata H, Fujisaki H, Takeguchi N 1990-01-01 4 NCIT:C17998 The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor. 39 PMID:11304936 biolink:Article Kwon D, Chae JB, Park CW, Kim YS, Lee SM, Kim EJ, Huh IH, Kim DY, Cho KD 2001-01-01 3 NCIT:C17998 Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo. 51 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021825s003lbl.pdf biolink:Publication 2015-01-01 PMID:9298526 biolink:Article Uneyama H, Takahara A, Dohmoto H, Yoshimoto R, Inoue K, Akaike N 1997-01-01 1 NCIT:C17998 Blockade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. 122 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019481s013lbl.pdf biolink:Publication 2015-01-01 PMID:4859983 biolink:Article Casdorph HR 1967-01-01 4 NCIT:C17998 Hypercholesteremia. Treatment with cholestyramine, a bile acid sequestering resin. 106 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016267s050lbl.pdf biolink:Publication 2011-01-01 PMID:2547493 biolink:Article Klöckner U, Isenberg G 1989-01-01 3 NCIT:C17998 The dihydropyridine niguldipine modulates calcium and potassium currents in vascular smooth muscle cells. 97 PMID:8287905 biolink:Article Tohse N, Takeda Y, Kanno M 1993-01-01 2 NCIT:C17998 Voltage-dependent modulation of L-type Ca2+ current by manidipine in guinea-pig heart cells. 249 PMID:7898101 biolink:Article Rosenthal J 1994-01-01 NLM:7902492 Nilvadipine: profile of a new calcium antagonist. An overview. 24 Suppl 2 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000802/WC500026565.pdf biolink:Publication 2016-01-01 PMID:22455413 biolink:Article Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S 2012-01-01 13 NLM:9801742 Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. 366 PMID:10533013 biolink:Article Wright RO, Lewander WJ, Woolf AD 1999-01-01 5 NLM:8002646 Methemoglobinemia: etiology, pharmacology, and clinical management. 34 PMID:12749884 biolink:Article Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, Mohr M 2003-01-01 11 NCIT:C17998 Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. 13 PMID:16891464 biolink:Article Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett NL, Rosen ST 2006-01-01 7 NCIT:C17998 Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. 5 PMID:9126675 biolink:Article Scholz H 1997-01-01 NCIT:C17998 Pharmacological aspects of calcium channel blockers. 10 Suppl 3 PMID:17213004 biolink:Article Park JY, Kim KA, Park PW, Lee OJ, Ryu JH, Lee GH, Ha MC, Kim JS, Kang SW, Lee KR 2006-01-01 11 NCIT:C17998 Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. 28 PMID:8821512 biolink:Article Guarneri L, Angelico P, Ibba M, Poggesi E, Taddei C, Leonardi A, Testa R 1996-01-01 1 NCIT:C17998 Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. 46 http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/077394lbl.pdf biolink:Publication 2005-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21160lbl.pdf biolink:Publication 2001-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022127s011lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019071s012lbl.pdf biolink:Publication 2009-01-01 PMID:18655903 biolink:Article Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G 2008-01-01 NCIT:C17998 Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. 170 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf biolink:Publication 2012-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020452s005lbl.pdf biolink:Publication 2010-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf biolink:Publication 2012-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020221s024lbl.pdf biolink:Publication 2008-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020038s033lbl.pdf biolink:Publication 2010-01-01 PMID:3025043 biolink:Article Yoshida T, Nishioka H, Yoshioka K, Nakano K, Kondo M, Terashima H 1987-01-01 1 NCIT:C17998 Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats. 36 PMID:1278093 biolink:Article Taurog A 1976-01-01 4 NCIT:C17998 The mechanism of action of the thioureylene antithyroid drugs. 98 PMID:6356910 biolink:Article Kerwar SS 1983-01-01 4B NLM:0267200 Pharmacologic properties of fenbufen. 75 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103767s5119lbl.pdf biolink:Publication 2011-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125036s0144lbl.pdf biolink:Publication 2012-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125118s179lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207155s000lbl.pdf biolink:Publication 2016-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125288s062lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf biolink:Publication 2016-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125509lbl.pdf biolink:Publication 2016-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf biolink:Publication 2016-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdf biolink:Publication 2008-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021846s101lbl.pdf biolink:Publication 2008-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205109s001lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020057s034lbl.pdf biolink:Publication 2006-01-01 http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/UCM200875.pdf biolink:Publication 2000-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf biolink:Publication 2015-01-01 PMID:20160034 biolink:Article Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J 2010-01-01 5 NCIT:C17998 Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. 70 PMID:18500360 biolink:Article Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H 2008-01-01 8 NCIT:C17998 Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. 154 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036Orig1s000lbledt.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/101063s5169lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf biolink:Publication 2015-01-01 PMID:2905151 biolink:Article Vincent J, Sumner DJ, Reid JL 1988-01-01 5 NLM:7503323 Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects. 26 PMID:1982751 biolink:Article Porszász J, Varga F, Porszász KG, Szolscányi J, Barthó L, Petöcz L, Kápolnai L 1990-01-01 12 NCIT:C17998 Pharmacology of the new H1-receptor antagonist setastine hydrochloride. 40 PMID:1354949 biolink:Article Rosenzweig P, Thebault JJ, Caplain H, Dubruc C, Bianchetti G, Fuseau E, Morselli PL 1992-01-01 2 NLM:0372346 Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine. 69 PMID:13499132 biolink:Article LENKE D 1957-01-01 11 NCIT:C17998 [Pharmacological effects of phathalazine and phthalazone derivatives. I]. 7 PMID:13757612 biolink:Article KOHOUT J, KORBOVA L, BLAZEK K 1961-01-01 NCIT:C17998 [Effect of anthistaminic drugs on the appearance of experimental gastric ulcer. III. Effect of mephenhydramine (alphadril) and polydroxyethylenesorbitanmonooleate on the appearance of gastric ulcers in guinea pigs]. 100 PMID:17404836 biolink:Article Ramadan ZB, Wrang ML, Tipton KF 2007-01-01 10 NCIT:C17998 Species differences in the selective inhibition of monoamine oxidase (1-methyl-2-phenylethyl)hydrazine and its potentiation by cyanide. 32 PMID:5889715 biolink:Article Gilmour SJ 1965-01-01 478 NCIT:C17998 Clinical trial of mebanazine--a new monoamine oxidase inhibitor. 111 PMID:19582593 biolink:Article Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, Kraus RL, Santarelli VP, Li Y, Barrow JC, Yang ZQ, Schlegel KA, Rittle KE, Reger TS, Bednar RA, Lemaire W, Mullen FA, Ballard JE, Tang C, Dai G, McManus OB, Koblan KS, Renger JJ 2009-01-01 2 NCIT:C17998 Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. 55 PMID:15931571 biolink:Article Brown WM 2001-01-01 12 NCIT:C17998 Taltirelin (Tanabe Seiyaku). 4 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf biolink:Publication 2015-01-01 PMID:15306801 biolink:Article Voets T, Droogmans G, Wissenbach U, Janssens A, Flockerzi V, Nilius B 2004-01-01 7001 NLM:0410462 The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels. 430 PMID:18305010 biolink:Article Ehlert FJ, Griffin MT 2008-01-01 3 NCIT:C17998 Two-state models and the analysis of the allosteric effect of gallamine at the M2 muscarinic receptor. 325 PMID:18258787 biolink:Article Shorter K, Farjo NP, Picksley SM, Randall VA 2008-01-01 6 NLM:8804484 Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. 22 PMID:8680742 biolink:Article Prior C, Tian L, el Mallah AI, Young L, Ward JM 1995-01-01 7 NCIT:C17998 Neuromuscular blocking profile of the vecuronium analogue, Org-9487, in the rat isolated hemidiaphragm preparation. 116 PMID:7551370 biolink:Article Hozawa S, Haruta Y, Ishioka S, Yamakido M 1995-01-01 4 Pt 1 NCIT:C17998 Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. 152 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf biolink:Publication 2014-01-01 PMID:17705685 biolink:Article Gille A, Bodor ET, Ahmed K, Offermanns S 2008-01-01 NCIT:C17998 Nicotinic acid: pharmacological effects and mechanisms of action. 48 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020766s035lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf biolink:Publication 2015-01-01 PMID:25349307 biolink:Article Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H 2014-01-01 12 NCIT:C17998 Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. 13 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020576s010lbl.pdf biolink:Publication 2010-01-01 PMID:26291199 biolink:Article Asaki T, Kuwano K, Morrison K, Gatfield J, Hamamoto T, Clozel M 2015-01-01 18 NCIT:C17998 Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension. 58 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207947s000lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf biolink:Publication 2015-01-01 PMID:17276408 biolink:Article Triggle DJ 2007-01-01 1 NCIT:C17998 Calcium channel antagonists: clinical uses--past, present and future. 74 PMID:10487332 biolink:Article Timmermans PB 1999-01-01 2 NCIT:C17998 Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. 22 PMID:1666418 biolink:Article Kubo M, Ochiai T, Kato J, Ishida R 1991-01-01 4 NCIT:C17998 Pharmacological studies on TA-6366, a new ACE inhibitor: II. Effect of long-term administration from the pre-hypertensive stage on blood pressure, relative heart weight and ACE activity of various tissues in spontaneously hypertensive rats (SHRs). 57 PMID:22047812 biolink:Article Kim JW, Kim JR, Yi S, Shin KH, Shin HS, Yoon SH, Cho JY, Kim DH, Shin SG, Jang IJ, Yu KS 2011-01-01 11 NCIT:C17998 Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. 33 PMID:8872297 biolink:Article Ziegler D, Haxhiu MA, Kaan EC, Papp JG, Ernsberger P 1996-01-01 NLM:7902492 Pharmacology of moxonidine, an I1-imidazoline receptor agonist. 27 Suppl 3 PMID:15716462 biolink:Article Fagart J, Seguin C, Pinon GM, Rafestin-Oblin ME 2005-01-01 5 NCIT:C17998 The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor. 67 PMID:21771637 biolink:Article Kolkhof P, Borden SA 2012-01-01 2 NCIT:C17998 Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. 350 PMID:19833635 biolink:Article Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR 2009-01-01 6 NLM:7513617 In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. 64 PMID:12173241 biolink:Article Scholz A 2002-01-01 1 NCIT:C17998 Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. 89 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201444s000lbl.pdf biolink:Publication 2011-01-01 PMID:7763301 biolink:Article Coley HM, Brooks N, Phillips DH, Hewer A, Jenkins TC, Jarman M, Judson IR 1995-01-01 9 NCIT:C17998 The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies. 49 PMID:6200290 biolink:Article Richards DM, Brogden RN, Heel RC, Speight TM, Avery GS 1984-01-01 3 NCIT:C17998 Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy. 27 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050778s021lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020645s008lbl.pdf biolink:Publication 2011-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019998s013lbl.pdf biolink:Publication 2007-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/008922s016lbl.pdf biolink:Publication 2009-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022252s004lbl.pdf biolink:Publication 2015-01-01 http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-09/mepronizine_ct_8952.pdf biolink:Publication 2011-01-01 PMID:15740719 biolink:Article Gimpl G, Postina R, Fahrenholz F, Reinheimer T 2005-01-01 1-2 NCIT:C17998 Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin. 510 https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2015-PI-01665-1 biolink:Publication 2015-01-01 PMID:9368911 biolink:Article Bruhwyler J, Liégeois JF, Géczy J 1997-01-01 1 NCIT:C17998 Pirlindole: a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties. 36 PMID:12781338 biolink:Article Hynson RM, Wouters J, Ramsay RR 2003-01-01 11 NCIT:C17998 Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure. 65 PMID:24900486 biolink:Article Rice KD, Aay N, Anand NK, Blazey CM, Bowles OJ, Bussenius J, Costanzo S, Curtis JK, Defina SC, Dubenko L, Engst S, Joshi AA, Kennedy AR, Kim AI, Koltun ES, Lougheed JC, Manalo JC, Martini JF, Nuss JM, Peto CJ, Tsang TH, Yu P, Johnston S 2012-01-01 5 NLM:101521073 Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). 3 PMID:18506437 biolink:Article Sahasranaman S, Howard D, Roy S 2008-01-01 8 NCIT:C17998 Clinical pharmacology and pharmacogenetics of thiopurines. 64 PMID:26171220 biolink:Article Jain MR, Giri SR, Trivedi C, Bhoi B, Rath A, Vanage G, Vyas P, Ranvir R, Patel PR 2015-01-01 3 NCIT:C17998 Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. 3 PMID:17005916 biolink:Article Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W, Schwartz JC 2007-01-01 1 NCIT:C17998 BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. 320 PMID:21615387 biolink:Article Schwartz JC 2011-01-01 4 NCIT:C17998 The histamine H3 receptor: from discovery to clinical trials with pitolisant. 163 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125338s085s087s088lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021877s005lbl.pdf biolink:Publication 2012-01-01 PMID:3207986 biolink:Article Thijssen HH, Baars LG, Vervoort-Peters HT 1988-01-01 3 NCIT:C17998 Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity. 95 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207533s000lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017588s040lbl.pdf biolink:Publication 2014-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf biolink:Publication 2021-01-01 PMID:16251241 biolink:Article Wikström B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, Ogasawara M, Kawashima Y, Ueno K, Mori A, Ueno Y 2005-01-01 12 NCIT:C17998 Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. 16 PMID:22084396 biolink:Article Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, Engst S, Johnston S, Friedman LS, Belvin M 2012-01-01 1 NCIT:C17998 Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. 72 http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20706slr011_emadine_lbl.pdf biolink:Publication 2003-01-01 PMID:24660890 biolink:Article Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe JT, Scapin G, Gao YD, Yan Y, Krueger D, Bak A, Eiermann G, He J, Cox J, Hicks J, Lyons K, He H, Salituro G, Tong S, Patel S, Doss G, Petrov A, Wu J, Xu SS, Sewall C, Zhang X, Zhang B, Thornberry NA, Weber AE 2014-01-01 8 NCIT:C17998 Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. 57 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205739s000lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021882s021lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207953s000lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021629s030lbl.pdf biolink:Publication 2015-01-01 PMID:1387020 biolink:Article Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T 1992-01-01 4 NCIT:C17998 Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. 105 PMID:10991983 biolink:Article Herrick-Davis K, Grinde E, Teitler M 2000-01-01 1 NCIT:C17998 Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. 295 PMID:11855658 biolink:Article Endoh M 2001-01-01 5 NCIT:C17998 Mechanism of action of Ca2+ sensitizers--update 2001. 15 PMID:10644512 biolink:Article Nagumo H, Sasaki Y, Ono Y, Okamoto H, Seto M, Takuwa Y 2000-01-01 1 NCIT:C17998 Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. 278 DOI:10.1016/S0168-8278(14)61094-1 biolink:Article N. Izumi, R. Tateishi, M. Seike, M. Kudo, H. Tamai, S. Kawazoe, K. Tanaka, M. Kurokawa, Y. Osaki, K. Yamamoto, M. Imawari 2014-01-01 1 NCIT:C17998 P933 ONCE-DAILY ORAL LUSUTROMBOPAG, ALTERNATIVE TO PLATELET TRANSFUSION IN THROMBOCYTOPENIC PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING RADIOFREQUENCY ABLATION: RESULTS FROM A PHASE 2B, RANDOMIZED, DOUBLE-BLIND STUDY 60 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125526Orig1s000Lbl.pdf biolink:Publication 2015-01-01 PMID:17652911 biolink:Article Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M 2007-01-01 3 NCIT:C17998 Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. 104 PMID:19967488 biolink:Article Ayuhara H, Takayanagi R, Okuyama K, Yoshimoto K, Ozeki T, Yokoyama H, Yamada Y 2009-01-01 6 NCIT:C17998 Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists. 14 PMID:1397053 biolink:Article Boeijinga PH, Galvan M, Baron BM, Dudley MW, Siegel BW, Slone AL 1992-01-01 1 NCIT:C17998 Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. 219 PMID:25271963 biolink:Article Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL 2014-01-01 20 NCIT:C17998 Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. 57 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf biolink:Publication 2015-01-01 PMID:15123680 biolink:Article Fu T, Mukhopadhyay D, Davidson NO, Borensztajn J 2004-01-01 27 NLM:2985121R The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions. 279 PMID:9405293 biolink:Article Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM 1998-01-01 NCIT:C17998 Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. 329 ( Pt 1) PMID:1546145 biolink:Article Dingemanse J, Berlin I, Payan C, Thiede HM, Puech AJ 1992-01-01 NCIT:C17998 Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects. 106 Suppl PMID:12177684 biolink:Article Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S 2002-01-01 2 NCIT:C17998 Pharmacology of flibanserin. 8 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf biolink:Publication 2015-01-01 PMID:20840530 biolink:Article Stahl SM, Sommer B, Allers KA 2011-01-01 1 NCIT:C17998 Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. 8 PMID:7878037 biolink:Article Double KL, Crocker AD 1995-01-01 5 NCIT:C17998 Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone. 92 PMID:12480161 biolink:Article Liu YC, Lo YK, Wu SN 2003-01-01 1 NCIT:C17998 Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells. 959 PMID:16004599 biolink:Article Jenner P 2005-01-01 6 NCIT:C17998 Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. 14 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103694s1008lbl.pdf biolink:Publication 2009-01-01 PMID:20209107 biolink:Article Humbert M, Castéran N, Letard S, Hanssens K, Iovanna J, Finetti P, Bertucci F, Bader T, Mansfield CD, Moussy A, Hermine O, Dubreuil P 2010-01-01 3 NCIT:C17998 Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. 5 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020572s016,020573s015lbl.pdf biolink:Publication 2009-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/09048slr037_methoxsalen_lbl.pdf biolink:Publication 2003-01-01 PMID:11556519 biolink:Article Henrotin Y, de Leval X, Mathy-Hartet M, Mouithys-Mickalad A, Deby-Dupont G, Dogné JM, Delarge J, Reginster JY 2001-01-01 8 NCIT:C17998 In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. 50 PMID:22497992 biolink:Article Duffy RA, Morgan C, Naylor R, Higgins GA, Varty GB, Lachowicz JE, Parker EM 2012-01-01 1 NCIT:C17998 Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. 102 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206500s000lbl.pdf biolink:Publication 2015-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004004/WC500192715.pdf biolink:Publication 2015-01-01 PMID:2001448 biolink:Article Gasson JC 1991-01-01 6 NLM:7603509 Molecular physiology of granulocyte-macrophage colony-stimulating factor. 77 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125141s219lbl.pdf biolink:Publication 2014-01-01 PMID:22686619 biolink:Article Subramaniam JM, Whiteside G, McKeage K, Croxtall JC 2012-01-01 9 NCIT:C17998 Mogamulizumab: first global approval. 72 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021665s005lbl.pdf biolink:Publication 2012-01-01 PMID:17234181 biolink:Article Mascia MP, Bachis E, Obili N, Maciocco E, Cocco GA, Sechi GP, Biggio G 2007-01-01 1-3 NCIT:C17998 Thiocolchicoside inhibits the activity of various subtypes of recombinant GABA(A) receptors expressed in Xenopus laevis oocytes. 558 PMID:26056160 biolink:Article Hammer H, Bader BM, Ehnert C, Bundgaard C, Bunch L, Hoestgaard-Jensen K, Schroeder OH, Bastlund JF, Gramowski-Voß A, Jensen AA 2015-01-01 2 NCIT:C17998 A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude). 88 PMID:20093397 biolink:Article Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Agai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z 2010-01-01 1 NCIT:C17998 Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. 333 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf biolink:Publication 2015-01-01 PMID:6285914 biolink:Article Rosenfeld RG, Aggarwal BB, Hintz RL, Dollar LA 1982-01-01 1 NCIT:C17998 Recombinant DNA-derived methionyl human growth hormone is similar in membrane binding properties to human pituitary growth hormone. 106 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf biolink:Publication 2015-01-01 PMID:8891469 biolink:Article Noble S, McTavish D 1996-01-01 4 NCIT:C17998 Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. 52 http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19853s012,014lbl.pdf biolink:Publication 2004-01-01 PMID:6121964 biolink:Article Walshe JM 1982-01-01 8273 NLM:2985213R Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. 1 PMID:10102460 biolink:Article Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, Hägg A, Jonsson T, Lapidus L, Leijd B, Stockelberg D, Säfwenberg U, Taghavi A, Thorsén M 1999-01-01 3 NCIT:C17998 Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. 81 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022037s011lbl.pdf biolink:Publication 2015-01-01 PMID:22633824 biolink:Article Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R 2012-01-01 9836 NLM:2985213R Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. 380 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103950s5150lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125559Orig1s000lbl.pdf biolink:Publication 2015-01-01 PMID:9205952 biolink:Article Alvarez-Guerra M, Alda O, Garay RP 1997-01-01 6 NCIT:C17998 Celiprolol: agonist and antagonist effects at cardiac beta 1- and vascular beta 2-adrenoceptors determined under in vivo conditions in the rat. 355 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103979s5135lbl.pdf biolink:Publication 2010-01-01 DOI: biolink:Article CAROPPO, R 1990-01-01 1 NCIT:C17998 EFFECT OF NIPEROTIDINE ON HYDROGEN-ION SECRETION AND ELECTRICAL PARAMETERS OF ISOLATED ASTRIC-MUCOSA 48 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000369/WC500053612.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204760s000lbl.pdf biolink:Publication 2014-01-01 PMID:22037049 biolink:Article Lewin AH, Miller GM, Gilmour B 2011-01-01 23 NCIT:C17998 Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class. 19 http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016419s029lbl.pdf biolink:Publication 2008-01-01 PMID:2139412 biolink:Article Santen RJ, Langecker P, Santner SJ, Sikka S, Rajfer J, Swerdloff R 1990-01-01 1 NCIT:C17998 Potency and specificity of CGS-16949A as an aromatase inhibitor. 16 PMID:2521224 biolink:Article Santen RJ, Demers LM, Adlercreutz H, Harvey H, Santner S, Sanders S, Lipton A 1989-01-01 1 NCIT:C17998 Inhibition of aromatase with CGS 16949A in postmenopausal women. 68 http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf biolink:Publication 2003-01-01 PMID:26131937 biolink:Article Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL 2015-01-01 NLM:0410462 Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf biolink:Publication 2015-01-01 PMID:1101049 biolink:Article Youdim MB 1975-01-01 NCIT:C17998 Monoamine oxidase. Its inhibition. 10 PMID:21186796 biolink:Article Zhang Z, Wallace MB, Feng J, Stafford JA, Skene RJ, Shi L, Lee B, Aertgeerts K, Jennings A, Xu R, Kassel DB, Kaldor SW, Navre M, Webb DR, Gwaltney SL 2011-01-01 2 NCIT:C17998 Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. 54 PMID:26115728 biolink:Article McKeage K 2015-01-01 NCIT:C17998 Trelagliptin: First Global Approval. PMID:11786663 biolink:Article Fukushima Y, Otsuka H, Ishikawa M, Asano T, Anai M, Katsube T, Ogawa K, Kajiwara T, Ohkawa S, Ishikawa T, Omata M, Saitoh T 2001-01-01 3 NCIT:C17998 Potent and long-lasting action of lafutidine on the human histamine H(2) receptor. 64 PMID:7703232 biolink:Article Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, Taskinen J 1995-01-01 13 NCIT:C17998 Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. 34 PMID:11160603 biolink:Article Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ 2001-01-01 2 NCIT:C17998 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. 296 PMID:24947465 biolink:Article Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T 2014-01-01 3 NCIT:C17998 Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. 350 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205422s000lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021106s036lbl.pdf biolink:Publication 2013-01-01 PMID:20600305 biolink:Article Millan MJ 2010-01-01 2 NCIT:C17998 From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. 128 PMID:15646370 biolink:Article Doi N, Hirotani C, Ukai K, Shimada O, Okuno T, Kurasaki S, Kiyofuji T, Ikegami R, Futamata M, Nakagawa T, Ase K, Chihara K 2004-01-01 12 NCIT:C17998 Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. 54 PMID:21668582 biolink:Article Sakata K, Someya M, Matsumoto Y, Tauchi H, Kai M, Toyota M, Takagi M, Hareyama M, Fukushima M 2011-01-01 9 NCIT:C17998 Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. 102 PMID:3114201 biolink:Article Tatsumi K, Fukushima M, Shirasaka T, Fujii S 1987-01-01 7 NCIT:C17998 Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. 78 PMID:8862723 biolink:Article Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M 1996-01-01 5 NCIT:C17998 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. 7 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020637s026lbl.pdf biolink:Publication 2013-01-01 PMID:2858236 biolink:Article Dukes ID, Vaughan Williams EM 1985-01-01 2 NCIT:C17998 Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile. 84 PMID:3924048 biolink:Article Bitonti AJ, Bacchi CJ, McCann PP, Sjoerdsma A 1985-01-01 10 NCIT:C17998 Catalytic irreversible inhibition of Trypanosoma brucei brucei ornithine decarboxylase by substrate and product analogs and their effects on murine trypanosomiasis. 34 PMID:21651906 biolink:Article Kawachi M, Matsunaga Y, Tanaka T, Hori Y, Ito K, Nagahama K, Ozaki T, Inoue N, Toda R, Yoshii K, Hirayama M, Kawabata Y, Takei M 2011-01-01 1-3 NCIT:C17998 Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. 666 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022249Orig1s019lbl.pdf biolink:Publication 2015-01-01 PMID:9726653 biolink:Article Fujimoto S, Ohashi M, Hiramoto A, Inoue Y, Nagai K, Shiokawa H, Itoh T 1998-01-01 2-3 NCIT:C17998 Vasorelaxant effect of olprinone, an inhibitor of phosphodiesterase 3, on mesenteric small artery and vein of rabbits. 353 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206334s000lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022011s013lbl.pdf biolink:Publication 2013-01-01 PMID:8723169 biolink:Article Abou-Mohamed G, Nagarajan R, Ibrahim TM, Caldwell RW 1996-01-01 1 NCIT:C17998 Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing. 10 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf biolink:Publication 2014-01-01 PMID:6114717 biolink:Article Van Wauwe J, Awouters F, Neimegeers CJ, Janssens F, Van Nueten JM, Janssen PA 1981-01-01 1 NCIT:C17998 In vivo pharmacology of astemizole, a new type of H1-antihistaminic compound. 251 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206333Orig1s000lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022575s012lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205123s008lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125103s146lbl.pdf biolink:Publication 2013-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002556/WC500148380.pdf biolink:Publication 2015-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf biolink:Publication 2021-01-01 PMID:23940628 biolink:Article Barrière DA, Mallet C, Blomgren A, Simonsen C, Daulhac L, Libert F, Chapuy E, Etienne M, Högestätt ED, Zygmunt PM, Eschalier A 2013-01-01 8 NCIT:C17998 Fatty acid amide hydrolase-dependent generation of antinociceptive drug metabolites acting on TRPV1 in the brain. 8 PMID:21828261 biolink:Article Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, Sachs G 2011-01-01 2 NCIT:C17998 Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). 339 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103946s5083lbl.pdf biolink:Publication 2009-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017808s036lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021999s029lbl.pdf biolink:Publication 2014-01-01 PMID:1696381 biolink:Article Fujii M, Okabayashi Y, Nakamura T, Tani S, Fujisawa T, Otsuki M 1990-01-01 4 NLM:8608542 Action of a new cholinergic agonist, aclatonium napadisilate, on isolated rat pancreatic acini. 5 http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/083220s041lbl.pdf biolink:Publication 2005-01-01 http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf biolink:Publication 2007-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002055/WC500127968.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s028lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021468s019lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021179Orig1s030lbl.pdf biolink:Publication 2014-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002465/WC500151313.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017563s023,020222s005lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21176lbl.pdf biolink:Publication 2000-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203284s001lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021271s006lbl.pdf biolink:Publication 2014-01-01 PMID:11740949 biolink:Article Castelli MP, Mocci I, Sanna AM, Gessa GL, Pani L 2001-01-01 2-3 NCIT:C17998 (-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2) receptors. 432 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125151s0184lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103234s5323lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125268s141lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125058s220lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf biolink:Publication 2010-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125460s000lbl.pdf biolink:Publication 2014-01-01 PMID:12825935 biolink:Article Renaud J, Bischoff SF, Buhl T, Floersheim P, Fournier B, Halleux C, Kallen J, Keller H, Schlaeppi JM, Stark W 2003-01-01 14 NCIT:C17998 Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands. 46 PMID:22671931 biolink:Article Wade PR, Palmer JM, McKenney S, Kenigs V, Chevalier K, Moore BA, Mabus JR, Saunders PR, Wallace NH, Schneider CR, Kimball ES, Breslin HJ, He W, Hornby PJ 2012-01-01 5 NCIT:C17998 Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist. 167 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022572s003lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020563s124lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206940s000lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018780s150lbl.pdf biolink:Publication 2015-01-01 PMID:23083772 biolink:Article Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA 2012-01-01 19 NCIT:C17998 Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. 60 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000885/WC500052310.pdf biolink:Publication 2015-01-01 PMID:26518 biolink:Article Galeone M, Moise G, Ferrante F, Cacioli D, Casula PL, Bignamini AA 1978-01-01 5 NCIT:C17998 Double-blind clinical comparison between a gastrin-receptor antagonist, proglumide, and a histamine H2-blocker, cimetidine. 5 PMID:2863192 biolink:Article Loewe CJ, Grider JR, Gardiner J, Vlahcevic ZR 1985-01-01 4 NCIT:C17998 Selective inhibition of pentagastrin- and cholecystokinin-stimulated exocrine secretion by proglumide. 89 PMID:2299627 biolink:Article Freidinger RM, Whitter WL, Gould NP, Holloway MK, Chang RS, Lotti VJ 1990-01-01 2 NCIT:C17998 Novel glutamic acid derived cholecystokinin receptor ligands. 33 PMID:28684 biolink:Article Falliers CJ, Redding MA, Katsampes CP 1978-01-01 3 NLM:0372346 Inhibition of cutaneous and mucosal allergy with phenyltoloxamine. 41 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020718s037lbl.pdf biolink:Publication 2013-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001012/WC500053998.pdf biolink:Publication 2014-01-01 PMID:17300164 biolink:Article Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, Aubin Y, Bateman KP, Chauret N, Day SH, Lévesque JF, Seto C, Silva JH, Trimble LA, Carriere MC, Denis D, Greig G, Kargman S, Lamontagne S, Mathieu MC, Sawyer N, Slipetz D, Abraham WM, Jones T, McAuliffe M, Piechuta H, Nicoll-Griffith DA, Wang Z, Zamboni R, Young RN, Metters KM 2007-01-01 4 NCIT:C17998 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). 50 PMID:25765567 biolink:Article Nassini R, Fusi C, Materazzi S, Coppi E, Tuccinardi T, Marone IM, De Logu F, Preti D, Tonello R, Chiarugi A, Patacchini R, Geppetti P, Benemei S 2015-01-01 NCIT:C17998 The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives. PMID:25171227 biolink:Article Sałat K, Jakubowska A, Kulig K 2014-01-01 10 NCIT:C17998 Zucapsaicin for the treatment of neuropathic pain. 23 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125422s025lbl.pdf biolink:Publication 2014-01-01 PMID:14681344 biolink:Article Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS 2004-01-01 1 NCIT:C17998 Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. 44 PMID:18638004 biolink:Article Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG 2008-01-01 11 NCIT:C17998 Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. 5 DOI:10.1002/jlcr.1116 biolink:Article Shin, Hyun-Il; Lee, Juyoung; Kim, Dae-Kee 2006-01-01 13 NCIT:C17998 Synthesis of 5-​ethyl-​2-​{5-​[4-​(2-​hydroxyethyl)​piperazin-​1-​ylsulfonyl]​-​2-​n-​propoxyphenyl}​-​7-​n-​propyl-​3,​5-​dihydro-​4H-​pyrrolo[3,​2-​d]​-​[2-​14C]​pyrimidin-​4-​one.2 HCl (14C-​SK3530.2 HCl) 49 PMID:24995399 biolink:Article Song W, Zhang X, Li S, Xu W 2015-01-01 3 NCIT:C17998 Design, synthesis, and preliminary activity evaluation of novel pyrimidine derivatives as acid pump antagonists. 85 PMID:6422042 biolink:Article Sestanj K, Bellini F, Fung S, Abraham N, Treasurywala A, Humber L, Simard-Duquesne N, Dvornik D 1984-01-01 3 NCIT:C17998 N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor. 27 PMID:10766174 biolink:Article Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH 2000-01-01 7 NCIT:C17998 A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. 60 PMID:8536820 biolink:Article Göke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, Kleist P, Arnold R, Lücker PW 1995-01-01 6 NCIT:C17998 Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. 56 PMID:9792651 biolink:Article Cotte N, Balestre MN, Phalipou S, Hibert M, Manning M, Barberis C, Mouillac B 1998-01-01 45 NLM:2985121R Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor. 273 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf biolink:Publication 2014-01-01 PMID:20530654 biolink:Article Gbahou F, Davenas E, Morisset S, Arrang JM 2010-01-01 3 NCIT:C17998 Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo. 334 PMID:7692441 biolink:Article Chen R, Lewis KA, Perrin MH, Vale WW 1993-01-01 19 NCIT:C17998 Expression cloning of a human corticotropin-releasing-factor receptor. 90 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=212 biolink:InformationResource PMID:21482695 biolink:Article Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, Clackson T 2011-01-01 6 NCIT:C17998 Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. 10 PMID:19536319 biolink:Article Ruhlmann C, Herrstedt J 2009-01-01 2 NLM:101253281 Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting. 5 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202799s001lbl.pdf biolink:Publication 2012-01-01 http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=61 biolink:InformationResource PMID:1828228 biolink:Article Demicheli C, Albertini JP, Garnier-Suillerot A 1991-01-01 2 NCIT:C17998 Interaction of mithramycin with DNA. Evidence that mithramycin binds to DNA as a dimer in a right-handed screw conformation. 198 PMID:7527033 biolink:Article Smith BL, Bauer GB, Povirk LF 1994-01-01 48 NLM:2985121R DNA damage induced by bleomycin, neocarzinostatin, and melphalan in a precisely positioned nucleosome. Asymmetry in protection at the periphery of nucleosome-bound DNA. 269 PMID:11502873 biolink:Article Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto S, Ohishi T, Soga T, Matsushime H, Furuichi K 2001-01-01 3 NCIT:C17998 Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. 60 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204958lbl.pdf biolink:Publication 2015-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001033/WC500043300.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf biolink:Publication 2004-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012911Orig1s033lbl.pdf biolink:Publication 2013-01-01 PMID:9315536 biolink:Article Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shattil SJ, Randolph A, Jakubowski JA, Jennings LK, Scarborough RM 1997-01-01 5 NCIT:C17998 Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. 96 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020912s021,020913s018lbl.pdf biolink:Publication 2015-01-01 PMID:1469694 biolink:Article Hartman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, Naylor AM, Manno PD, Lynch RJ, Zhang G 1992-01-01 24 NCIT:C17998 Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. 35 PMID:23063522 biolink:Article Wang J, Mook RA, Lu J, Gooden DM, Ribeiro A, Guo A, Barak LS, Lyerly HK, Chen W 2012-01-01 22 NCIT:C17998 Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling. 20 PMID:22042473 biolink:Article Fendrich V, Wiese D, Waldmann J, Lauth M, Heverhagen AE, Rehm J, Bartsch DK 2011-01-01 5 NCIT:C17998 Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms. 254 PMID:21073468 biolink:Article Miller GM 2011-01-01 2 NCIT:C17998 The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. 116 PMID:2472386 biolink:Article Bayne ML, Applebaum J, Underwood D, Chicchi GG, Green BG, Hayes NS, Cascieri MA 1989-01-01 19 NLM:2985121R The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor. 264 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021839s016lbl.pdf biolink:Publication 2014-01-01 PMID:21976485 biolink:Article Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu PA 2011-01-01 46 NCIT:C17998 Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. 108 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf biolink:Publication 2012-01-01 PMID:20030735 biolink:Article Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bönisch H 2010-01-01 6 NCIT:C17998 Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. 24 PMID:15017615 biolink:Article Atherton C, Jones J, McKaig B, Bebb J, Cunliffe R, Burdsall J, Brough J, Stevenson D, Bonner J, Rordorf C, Scott G, Branson J, Hawkey CJ 2004-01-01 2 NCIT:C17998 Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study. 2 PMID:10794682 biolink:Article Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K 2000-01-01 9 NCIT:C17998 N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. 43 PMID:18060946 biolink:Article Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN 2007-01-01 6 NLM:0370476 Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. 197 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021945s005lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125031s082lbl.pdf biolink:Publication 2007-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5184lbl.pdf biolink:Publication 2015-01-01 PMID:20022913 biolink:Article Meyerhof W, Batram C, Kuhn C, Brockhoff A, Chudoba E, Bufe B, Appendino G, Behrens M 2010-01-01 2 NCIT:C17998 The molecular receptive ranges of human TAS2R bitter taste receptors. 35 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022276s003lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203568s004lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022264s013s014lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206619s003lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021756s018lbl.pdf biolink:Publication 2011-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000Lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206143Orig1s000lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/016466s046lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203214s007lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103795s5548lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103792s5311lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020261s048,021192s021lbl.pdf biolink:Publication 2012-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021174s020lbl.pdf biolink:Publication 2006-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020986s059s081lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125486_s008lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125019s210s213lbl.pdf biolink:Publication 2013-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021536s031s051lbl.pdf biolink:Publication 2015-01-01 PMID:8950316 biolink:Article Uchiyama-Tsuyuki Y, Saitoh M, Muramatsu M 1996-01-01 25-26 NCIT:C17998 Identification and characterization of the 5-HT4 receptor in the intestinal tract and striatum of the guinea pig. 59 PMID:8483969 biolink:Article Blandizzi C, Mengozzi G, Intorre L, Natale G, Soldani G, Del Tacca M 1993-01-01 4 NCIT:C17998 Inhibitory cholinergic effects of esaprazole on gastric secretion and plasma gastrin levels in the dog. 46 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf biolink:Publication 2015-01-01 PMID:15542782 biolink:Article Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL 2004-01-01 11 NCIT:C17998 Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. 3 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf biolink:Publication 2015-01-01 PMID:17943726 biolink:Article Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M 2008-01-01 3 NCIT:C17998 E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. 122 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021912s013lbl.pdf biolink:Publication 2014-01-01 PMID:12090787 biolink:Article Handley DA, Senanayake CH, Dutczak W, Benovic JL, Walle T, Penn RB, Wilkinson HS, Tanoury GJ, Andersson RG, Johansson F, Morley J 2002-01-01 2 NCIT:C17998 Biological actions of formoterol isomers. 15 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf biolink:Publication 2015-01-01 PMID:23913691 biolink:Article Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Réville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL 2013-01-01 39 NLM:2985121R Kinetics of avibactam inhibition against Class A, C, and D β-lactamases. 288 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000532/WC500040171.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603s015lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011757s103lbl.pdf biolink:Publication 2014-01-01 PMID:25120077 biolink:Article Hida H, Mouri A, Mori K, Matsumoto Y, Seki T, Taniguchi M, Yamada K, Iwamoto K, Ozaki N, Nabeshima T, Noda Y 2015-01-01 3 NCIT:C17998 Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC. 40 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021879s005lbl.pdf biolink:Publication 2015-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002294/WC500117862.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205776s000lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/20920s033lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s367lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021081s062lbl.pdf biolink:Publication 2015-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002548/WC500182307.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022505s004lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202057s009lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020280s077lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf biolink:Publication 2014-01-01 PMID:12482421 biolink:Article Ohwada J, Tsukazaki M, Hayase T, Oikawa N, Isshiki Y, Fukuda H, Mizuguchi E, Sakaitani M, Shiratori Y, Yamazaki T, Ichihara S, Umeda I, Shimma N 2003-01-01 2 NCIT:C17998 Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole. 13 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125516s000lbl.pdf biolink:Publication 2015-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000773/WC500045832.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125370s053lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103575s5126lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125326s060lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125319s081lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/103749s5059lbl.pdf biolink:Publication 2005-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s063lbl.pdf biolink:Publication 2015-01-01 PMID:24936658 biolink:Article Benod C, Villagomez R, Filgueira CS, Hwang PK, Leonard PG, Poncet-Montange G, Rajagopalan S, Fletterick RJ, Gustafsson JÅ, Webb P 2014-01-01 6 NCIT:C17998 The human orphan nuclear receptor tailless (TLX, NR2E1) is druggable. 9 PMID:9112065 biolink:Article Hoogkamer JF, Kleinbloesem CH, Nokhodian A, Ouwerkerk MJ, Lankhaar G, Ungethüm W, Kirch W 1997-01-01 6 NCIT:C17998 Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function. 51 PMID:3000389 biolink:Article Takeyama K, Minato H, Fukuya F, Kawahara S, Hosoki K, Kadokawa T 1985-01-01 10 NCIT:C17998 Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs. 35 PMID:2419701 biolink:Article Holck M, Fischli W, Hefti F, Gerold M 1986-01-01 1 NLM:7902492 Cardiovascular effects of the new angiotensin-converting-enzyme inhibitor, cilazapril, in anesthetized and conscious dogs. 8 PMID:2484083 biolink:Article DeForrest JM, Waldron TL, Krapcho J, Turk C, Rubin B, Powell JR, Cushman DW, Petrillo EW 1989-01-01 6 NLM:7902492 Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. 13 PMID:8427943 biolink:Article Suzuki H, Kawaratani T, Shioya H, Uji Y, Saruta T 1993-01-01 1 NCIT:C17998 Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans. 14 PMID:6782492 biolink:Article Schrör K, Sauerland S, Kuhn A, Rösen R 1980-01-01 1 NCIT:C17998 Different sensitivities of prostaglandin-cyclooxygenases in blood platelets and coronary arteries against non-steroidal antiinflammatory drugs. 313 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085s305lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125409s104lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125377s055lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125075s130lbl.pdf biolink:Publication 2009-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125349s000lbl.pdf biolink:Publication 2012-01-01 DOI:10.1111/j.1527-3458.1998.tb00067.x biolink:Article Kojima, Jun; Onodera, Kenji; Ozeki, Mitsuo; Nakayama, Kunio 1998-01-01 3 NLM:9514898 Ipidacrine (NIK-247): A Review of Multiple Mechanisms as an Antidementia Agent 4 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf biolink:Publication 2014-01-01 PMID:9530547 biolink:Article Gunasekara NS, Faulds D 1998-01-01 3 NCIT:C17998 Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. 55 PMID:11431468 biolink:Article Chao SH, Price DH 2001-01-01 34 NLM:2985121R Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. 276 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125320s170lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125261s114lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125289s094lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125160s215lbl.pdf biolink:Publication 2013-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125166s368s380lbl.pdf biolink:Publication 2014-01-01 isbn:0071624422 Book Laurence L. Brunton & Bruce A. Chabner & Bjorn C. Knollmann 2011-01-01 Goodman and Gilman's The Pharmacological Basis of Therapeutics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000666/WC500021287.pdf biolink:Publication 2009-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125104s840s847s889lbl.pdf biolink:Publication 2013-01-01 PMID:15869320 biolink:Article 2005-01-01 3 NCIT:C17998 Cilansetron: KC 9946. 6 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202292s000lbl.pdf biolink:Publication 2012-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125156s106lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103976s5161lbl.pdf biolink:Publication 2014-01-01 PMID:18974361 biolink:Article Perez-Reyes E, Van Deusen AL, Vitko I 2009-01-01 2 NCIT:C17998 Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. 328 PMID:1281221 biolink:Article Cohen CJ, Spires S, Van Skiver D 1992-01-01 4 NCIT:C17998 Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. 100 PMID:18306243 biolink:Article LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM 2008-01-01 3 NCIT:C17998 Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). 63 PMID:17616698 biolink:Article Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK 2007-01-01 13 NCIT:C17998 Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. 67 PMID:22080169 biolink:Article Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, Zhang J, Dong M, Du X, Lu XP 2012-01-01 4 NCIT:C17998 Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. 69 PMID:11309480 biolink:Article Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E 2001-01-01 9 NCIT:C17998 The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. 98 PMID:19010832 biolink:Article Morris PG, Fornier MN 2008-01-01 22 NCIT:C17998 Microtubule active agents: beyond the taxane frontier. 14 PMID:21466810 biolink:Article Inayoshi A, Sugimoto Y, Funahashi J, Takahashi S, Matsubara M, Kusaka H 2011-01-01 19-20 NCIT:C17998 Mechanism underlying the block of human Cav3.2 T-type Ca2+ channels by benidipine, a dihydropyridine Ca2+ channel blocker. 88 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103772s5370lbl.pdf biolink:Publication 2015-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103705s5432lbl.pdf biolink:Publication 2014-01-01 PMID:1717223 biolink:Article 1991-01-01 2 NCIT:C17998 Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders 42 PMID:24558448 biolink:Article 2014-01-01 2 NCIT:C17998 Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors 9 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214012Orig1s000PharmR.pdf biolink:Publication 2021-01-01 PMID:16274260 biolink:Article 2005-01-01 6 NCIT:C17998 Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity 6 PMID:1620298 biolink:Article 1992-01-01 3 NCIT:C17998 Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage 30 PMID:1983712 biolink:Article 1990-01-01 5 NCIT:C17998 The effect of the H2-antagonist niperotidine on intragastric acidity in healthy subjects undergoing 24-hour pH-monitoring 22 PMID:21709094 biolink:Article 2011-01-01 9 NCIT:C17998 In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions 55 http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500005871.pdf biolink:Publication 2008-01-01 PMID:10878285 biolink:Article Allison AC, Eugui EM 2000-01-01 2-3 NLM:7902474 Mycophenolate mofetil and its mechanisms of action. 47 PMID:17915852 biolink:Article Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, Edmondson DE, Mattevi A 2007-01-01 23 NCIT:C17998 Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. 50 PMID:17030736 biolink:Article Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P, Fariello RG 2006-01-01 7 Suppl 2 NCIT:C17998 Safinamide: from molecular targets to a new anti-Parkinson drug. 67 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022275s014lbl.pdf biolink:Publication 2014-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000679/WC500037902.pdf biolink:Publication 2011-01-01 PMID:24872026 biolink:Article Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, Singh S, Wong S, Garner N, Leblanc H, Bunch RT, Blanset D, Selby MJ, Korman AJ 2014-01-01 9 NCIT:C17998 In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. 2 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002430/WC500133771.pdf biolink:Publication 2012-01-01 PMID:14599363 biolink:Article Witte DG, Cassar SC, Masters JN, Esbenshade T, Hancock AA 2002-01-01 5 NCIT:C17998 Use of a fluorescent imaging plate reader--based calcium assay to assess pharmacological differences between the human and rat vanilloid receptor. 7 http://www.hsc.nihr.ac.uk/files/downloads/2226/2524.a929981f.Zucapsaicin_Nov13.pdf biolink:InformationResource http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf biolink:Publication 2014-01-01 http://www.pmda.go.jp/english/service/pdf/drugs/remitch_jan2009_e.pdf biolink:Publication 2009-01-01 PMID:17071817 biolink:Article Su S, Ohno Y, Lossin C, Hibino H, Inanobe A, Kurachi Y 2007-01-01 2 NCIT:C17998 Inhibition of astroglial inwardly rectifying Kir4.1 channels by a tricyclic antidepressant, nortriptyline. 320 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022036lbl.pdf biolink:Publication 2010-01-01 PMID:2445740 biolink:Article Schmid-Antomarchi H, De Weille J, Fosset M, Lazdunski M 1987-01-01 33 NLM:2985121R The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells. 262 PMID:21486038 biolink:Article Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB 2011-01-01 9 NCIT:C17998 Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. 54 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204447s004lbl.pdf biolink:Publication 2014-01-01 PMID:15322733 biolink:Article Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M 2004-01-01 2 NCIT:C17998 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. 370 PMID:11716850 biolink:Article Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, Seino S 2001-01-01 1 NCIT:C17998 The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. 431 PMID:10742287 biolink:Article Gopalakrishnan M, Molinari EJ, Shieh CC, Monteggia LM, Roch JM, Whiteaker KL, Scott VE, Sullivan JP, Brioni JD 2000-01-01 7 NCIT:C17998 Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells. 129 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103691s5095lbl.pdf biolink:Publication 2011-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020807s011lbl.pdf biolink:Publication 2006-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125277s071lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdf biolink:Publication 2014-01-01 PMID:15331566 biolink:Article Baggio LL, Huang Q, Brown TJ, Drucker DJ 2004-01-01 9 NCIT:C17998 A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. 53 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021289s019lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21322lbl.pdf biolink:Publication 2004-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20367s066lbl.pdf biolink:Publication 2005-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125276s092lbl.pdf biolink:Publication 2013-01-01 PMID:23253932 biolink:Article Patel DD, Lee DM, Kolbinger F, Antoni C 2013-01-01 NCIT:C17998 Effect of IL-17A blockade with secukinumab in autoimmune diseases. 72 Suppl 2 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103770s5185lbl.pdf biolink:Publication 2014-01-01 PMID:16399882 biolink:Article Petroski RE, Pomeroy JE, Das R, Bowman H, Yang W, Chen AP, Foster AC 2006-01-01 1 NCIT:C17998 Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors. 317 PMID:11755161 biolink:Article Noguchi H, Kitazumi K, Mori M, Shiba T 2002-01-01 1-2 NCIT:C17998 Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic. 434 PMID:23279183 biolink:Article Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, Akita K, Kirii Y 2013-01-01 2 NCIT:C17998 Activity-based kinase profiling of approved tyrosine kinase inhibitors. 18 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021938s027lbl.pdf biolink:Publication 2014-01-01 PMID:21575866 biolink:Article Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, Oikawa N, Tsukuda T, Ishii N, Aoki Y 2011-01-01 5 NLM:101130617 CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. 19 PMID:20163176 biolink:Article McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ 2010-01-01 6 NCIT:C17998 Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. 53 GOOGLE_PATENT:US20080064681A1 biolink:InformationContentEntity 2008-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003906/WC500181492.pdf biolink:Publication 2015-01-01 PMID:18672868 biolink:Article Pinto-Bazurco Mendieta MA, Negri M, Jagusch C, Müller-Vieira U, Lauterbach T, Hartmann RW 2008-01-01 16 NCIT:C17998 Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. 51 http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/basnova032301LB.pdf biolink:Publication 2001-01-01 PMID:12191614 biolink:Article Sasaki Y, Suzuki M, Hidaka H 2002-01-01 2-3 NCIT:C17998 The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. 93 PMID:25414122 biolink:Article Garnock-Jones KP 2014-01-01 18 NCIT:C17998 Ripasudil: first global approval. 74 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125511s000lbl.pdf biolink:Publication 2015-01-01 PMID:11830761 biolink:Article Lapin I 2001-01-01 4 NCIT:C17998 Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. 7 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020788s024lbl.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125418s020lbl.pdf biolink:Publication 2013-01-01 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000916/WC500038317.pdf biolink:Publication 2014-01-01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019810s098,022056s014lbl.pdf biolink:Publication 2014-01-01 PMID:9520489 biolink:Article Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF 1998-01-01 7 NCIT:C17998 Calcimimetics with potent and selective activity on the parathyroid calcium receptor. 95 PMID:15200144 biolink:Article Breitwieser GE, Miedlich SU, Zhang M 2004-01-01 3 NLM:8006226 Calcium sensing receptors as integrators of multiple metabolic signals. 35 PMID:19751980 biolink:Article Aurelio L, Valant C, Figler H, Flynn BL, Linden J, Sexton PM, Christopoulos A, Scammells PJ 2009-01-01 20 NCIT:C17998 3- and 6-Substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines as A1 adenosine receptor allosteric modulators and antagonists. 17 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125477s007lbl.pdf biolink:Publication 2014-01-01 PMID:24169554 biolink:Article Gingell JJ, Burns ER, Hay DL 2014-01-01 1 NCIT:C17998 Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors. 155 isbn:0853699143 Book Karen Baxter 2010-01-01 Stockley's Drug Interactions PMID:19661462 biolink:Article 2009-01-01 NCIT:C17998 Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity. PMID:18500680 biolink:Article 2008-01-01 NCIT:C17998 Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats. PMID:19428599 biolink:Article 2009-01-01 NCIT:C17998 T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. PMID:19783139 biolink:Article 2009-01-01 NCIT:C17998 Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. PMID:22139434 biolink:Article 2012-01-01 NCIT:C17998 Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. PMID:20302302 biolink:Article 2010-01-01 NCIT:C17998 (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucito l (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. PMID:22889351 biolink:Article 2012-01-01 NCIT:C17998 Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. PMID:12519058 biolink:Article 2003-01-01 NCIT:C17998 Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase. PMID:22959556 biolink:Article 2012-01-01 NCIT:C17998 Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-y lcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. PMID:20959606 biolink:Article 2011-01-01 NLM:7603509 CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. PMID:22019046 biolink:Article 2011-01-01 NCIT:C17998 Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methyl pyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. PMID:20863829 biolink:Article 2010-01-01 NCIT:C17998 Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. PMID:20565075 biolink:Article 2010-01-01 NCIT:C17998 Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. PMID:25043012 biolink:Article 2014-01-01 NLM:0410462 Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. PMID:21502615 biolink:Article 2011-01-01 NCIT:C17998 In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. PMID:11302816 biolink:Article 2001-01-01 NCIT:C17998 In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. PMID:20410884 biolink:Article 2010-01-01 NLM:0410462 Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. PMID:17293563 biolink:Article 2007-01-01 NCIT:C17998 Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. PMID:23742252 biolink:Article 2013-01-01 NCIT:C17998 Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. PMID:18447380 biolink:Article 2008-01-01 NCIT:C17998 Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. PMID:22058426 biolink:Article 2012-01-01 NCIT:C17998 Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. PMID:23499664 biolink:Article 2013-01-01 NLM:236217 Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. PMID:19256507 biolink:Article 2009-01-01 NCIT:C17998 Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihy dro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. PMID:21985634 biolink:Article 2012-01-01 NCIT:C17998 Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. PMID:2164086 biolink:Article 1990-01-01 NCIT:C17998 BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. PMID:10454045 biolink:Article 1999-01-01 NCIT:C17998 [3H]AL-5848 ([3H]9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. PMID:22640220 biolink:Article 2012-01-01 NLM:101269163 Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system. PMID:20371707 biolink:Article 2010-01-01 NCIT:C17998 Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. PMID:18417092 biolink:Article 2008-01-01 NCIT:C17998 Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010. PMID:19317446 biolink:Article 2009-01-01 NCIT:C17998 Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists. PMID:22171087 biolink:Article 2012-01-01 NCIT:C17998 Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. PMID:19263460 biolink:Article 2009-01-01 NLM:101259013 Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. PMID:11256231 biolink:Article 2000-01-01 NLM:7909595 Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. PMID:22862294 biolink:Article 2012-01-01 NCIT:C17998 The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. PMID:17154430 biolink:Article 2007-01-01 NLM:101259013 Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. PMID:20845908 biolink:Article 2010-01-01 NCIT:C17998 Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. PMID:18678486 biolink:Article 2008-01-01 NCIT:C17998 Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. PMID:10461840 biolink:Article 1999-01-01 NCIT:C17998 Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections. PMID:9559824 biolink:Article 1998-01-01 NCIT:C17998 In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. PMID:12939461 biolink:Article 2003-01-01 NCIT:C17998 Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. PMID:17588934 biolink:Article 2007-01-01 NCIT:C17998 An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf biolink:Publication 2021-01-01 PMID:23601816 biolink:Article 2013-01-01 NCIT:C17998 Synthesis and biological evaluation of Esaprazole analogues showing sigma1 binding and neuroprotective properties in vitro. PMID:20503967 biolink:Article 2010-01-01 NCIT:C17998 Factor Xa inhibitors: next-generation antithrombotic agents. PMID:16332435 biolink:Article 2006-01-01 NCIT:C17998 Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists. PMID:24320933 biolink:Article 2014-01-01 NCIT:C17998 Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. PMID:18232657 biolink:Article 2008-01-01 NCIT:C17998 Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor. PMID:17872968 biolink:Article 2007-01-01 NCIT:C17998 The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. PMID:10428387 biolink:Article 1999-01-01 NCIT:C17998 Synthesis and antimuscarinic activity of a series of 4-(1-Imidazolyl)-2,2-diphenylbutyramides: discovery of potent and subtype-selective antimuscarinic agents. PMID:19522465 biolink:Article 2009-01-01 NCIT:C17998 Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). PMID:18570382 biolink:Article 2008-01-01 NCIT:C17998 Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex. PMID:22264484 biolink:Article 2012-01-01 NCIT:C17998 Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. PMID:20590641 biolink:Article 2010-01-01 NCIT:C17998 Molecular determinants of state-dependent block of voltage-gated sodium channels by pilsicainide. PMID:18800822 biolink:Article 2008-01-01 NCIT:C17998 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. PMID:22869577 biolink:Article 2012-01-01 NCIT:C17998 Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). PMID:1830563 biolink:Article 1991-01-01 NCIT:C17998 Ro 42-5892 is a potent orally active renin inhibitor in primates. PMID:18299583 biolink:Article 2008-01-01 NLM:7505876 Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. PMID:21651903 biolink:Article 2011-01-01 NCIT:C17998 Pregabalin is a potent and selective ligand for alpha(2)delta-1 and alpha(2)delta-2 calcium channel subunits. PMID:8839659 biolink:Article 1996-01-01 NCIT:C17998 Antimuscarinic effect of tiquizium bromide in vitro and in vivo. PMID:24508831 biolink:Article 2014-01-01 NCIT:C17998 Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease. PMID:2851680 biolink:Article 1988-01-01 NCIT:C17998 Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor. PMID:3021350 biolink:Article 1986-01-01 NCIT:C17998 Design and synthesis of N-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L -alanyl]-N-(indan-2-yl)glycine (CV-3317), a new, potent angiotensin converting enzyme inhibitor. PMID:8891872 biolink:Article 1996-01-01 NLM:7902492 Affinity of angiotensin I-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ACE is different in heart, lung, arteries, and veins. PMID:12510841 biolink:Article 2002-01-01 NCIT:C17998 Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. PMID:10976457 biolink:Article 2000-01-01 NLM:420550 [Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia]. PMID:2572952 biolink:Article 1989-01-01 NCIT:C17998 The partial opiate receptor agonists, dezocine and ciramadol act as mu receptor antagonists at the feline ileocecal sphincter. PMID:19153939 biolink:Article 2009-01-01 NLM:8402938 A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction. PMID:5224878 biolink:Article 1966-01-01 NCIT:C17998 Octapressin as a vasoconstrictor in dental plexus anesthesia. PMID:17179482 biolink:Article 2006-01-01 NCIT:C17998 Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. PMID:21669536 biolink:Article 2011-01-01 NCIT:C17998 Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase. PMID:17275317 biolink:Article 2007-01-01 NCIT:C17998 Synthesis and structure-activity relationships of novel warfarin derivatives. PMID:6148400 biolink:Article 1984-01-01 NCIT:C17998 Determination of biological activity of adinazolam and its metabolites. PMID:10720420 biolink:Article 2000-01-01 NCIT:C17998 The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. PMID:1775162 biolink:Article 1991-01-01 NCIT:C17998 Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action. PMID:15686911 biolink:Article 2005-01-01 NCIT:C17998 Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent. PMID:15494035 biolink:Article 2004-01-01 NCIT:C17998 Amylin receptors: molecular composition and pharmacology. PMID:15126366 biolink:Article 2004-01-01 NCIT:C17998 Characterization of the interaction of ingenol 3-angelate with protein kinase C. PMID:2165421 biolink:Article 1990-01-01 NLM:0217513 Flux-dependent increase in the stoichiometry of charge translocation by mitochondrial ATPase/ATP synthase induced by almitrine. PMID:23647933 biolink:Article 2013-01-01 NLM:9010756 Dronedarone's inhibition of If current is the primary mechanism responsible for its bradycardic effect. PMID:24400777 biolink:Article 2014-01-01 NCIT:C17998 Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. PMID:22470110 biolink:Article 2012-01-01 NCIT:C17998 Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors. PMID:24102143 biolink:Article 2014-01-01 NCIT:C17998 Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. PMID:9347318 biolink:Article 1997-01-01 NCIT:C17998 Antagonistic effects of isofloxythepin on dopamine D1 and D2 receptors and behaviors in rats. PMID:24786236 biolink:Article 2014-01-01 NLM:100956087 Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6(*)1 and CYP2D6(*)10 using cell-based models in vitro. PMID:12388666 biolink:Article 2002-01-01 NCIT:C17998 Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. PMID:2907502 biolink:Article 1988-01-01 3 NLM:420550 Pharmacological investigation of bezafibrate, a hypolipidemic agent. II. Mechanism of the hypolipidemic action of bezafibrate in rats 92 PMID:4396765 biolink:Article 1971-01-01 10 NCIT:C17998 A comparison of the effects of noradrenaline, adrenaline and some phenylephrine derivatives on alpha-, beta- and beta- adrenergic receptors 45 PMID:23859232 biolink:Article 2013-01-01 9 NCIT:C17998 A review on leukotrienes and their receptors with reference to asthma 50 PMID:23928358 biolink:Article 2013-01-01 40 NLM:2985121R VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapy 288 PMID:17877367 biolink:Article 2007-01-01 40 NCIT:C17998 Molecular identification of the human melanocortin-2 receptor responsible for ligand binding and signaling 46 PMID:23319593 biolink:Article 2013-01-01 9 NLM:2985121R Hydralazine and organic nitrates restore impaired excitation-contraction coupling by reducing calcium leak associated with nitroso-redox imbalance 288 PMID:19466525 biolink:Article 2009-01-01 3 NCIT:C17998 Effect of edaravone, a novel free radical scavenger, supplemented to cardioplegia on myocardial function after cardioplegic arrest: in vitro study of isolated rat heart 24 http://professional.diabetes.org/Content/Posters/2008/p502-P.pdf biolink:InformationResource PMID:10427 biolink:Article Harms HH 1976-01-01 2 NCIT:C17998 Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors 199 PMID:23393163 biolink:Article 2013-01-01 5 NCIT:C17998 Vesnarinone suppresses TNFalpha mRNA expression by inhibiting valosin-containing protein 83 PMID:8405122 biolink:Article 1993-01-01 1 NCIT:C17998 Ca2+(-)dependent and Ca2+(-)independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors 240 PMID:15212190 biolink:Article 2004-01-01 5 NCIT:C17998 Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma 54 http://eisai.jp/medical/products/di/EPI/COR_A_EPI.pdf biolink:Publication 2009-01-01 Coretec Injection 5 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125557lbl.pdf biolink:Publication 2014-01-01 PMID:10364735 biolink:Article 1999-01-01 3 NCIT:C17998 Reproterol: beta-2-agonist, theophylline, or both? 66 PMID:22037378 biolink:Article 2011-01-01 11 NLM:9604648 Comprehensive analysis of kinase inhibitor selectivity 29 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf biolink:Publication 2019-01-01 PMID:27003761 biolink:Article Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P 2016-01-01 7 NCIT:C17998 Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor 59 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf biolink:Publication 2019-01-01 PMID:30886973 biolink:Article Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, Camp HS, Padley RJ, George JS, Hyland D, Rosebraugh M, Wishart N, Olson L, Long AJ 2018-01-01 23 NCIT:C17998 In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) 2 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf biolink:Publication 2019-01-01 PMID:18394554 biolink:Article Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG 2008-01-01 4 NLM:101130617 Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. 13 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210828s000lbl.pdf biolink:Publication 2019-01-01 PMID:28495802 biolink:Article Yin J, Tse CM, Cha B, Sarker R, Zhu XC, Walentinsson A, Greasley PJ, Donowitz M 2017-01-01 2 NLM:100901227 A common NHE3 single-nucleotide polymorphism has normal function and sensitivity to regulatory ligands 313 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf biolink:Publication 2019-01-01 PMID:29706423 biolink:Article Thoreau E, Arlabosse JM, Bouix-Peter C, Chambon S, Chantalat L, Daver S, Dumais L, Duvert G, Feret A, Ouvry G, Pascau J, Raffin C, Rodeville N, Soulet C, Tabet S, Talano S, Portal T 2018-01-01 10 NCIT:C17998 Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne 28 PMID:20855361 biolink:Article Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, Xu YC 2010-01-01 10 NCIT:C17998 Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan 30 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf biolink:Publication 2019-01-01 PMID:31381333 biolink:Article Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, Tang Z, Song H, Guo Y, Liu X, Su D, Zhang S, Song X, Zhou X, Hong Y, Chen S, Cheng Z, Young S, Wei Q, Wang H, Wang Q, Lv L, Wang F,Xu H, Sun H, Xing H, Li N, Zhang W, Wang Z, Liu G, Sun Z, Zhou D, Li W, Liu L, Wang L, Wang Z 2019-01-01 17 NCIT:C17998 Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase 62 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf biolink:Publication 2019-01-01 PMID:27378309 biolink:Article Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, Patskovsky Y, Almo SC, Sinha U, Metcalf BW, Archer DR 2016-01-01 1 NCIT:C17998 GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease 175 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211970s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761136lbl.pdf biolink:Publication 2019-01-01 PMID:24658078 biolink:Article Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, Davies MV, Alexander MJ, Devine M, Loveday KS, Underwood KW, Grinberg AV, Quisel JD, Chopra R, Pearsall RS, Seehra J, Kumar R 2014-01-01 4 NLM:9502015 Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis 20 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf biolink:Publication 2019-01-01 PMID:27013195 biolink:Article Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, Capo L, Verlinsky A, Leavitt M, Malik F, Avina H, Guevara CI, Dinh N, Karki S, Anand BS, Pereira DS, Joseph IB, Doñate F, Morrison K, Stover DR 2016-01-01 10 NCIT:C17998 Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models 76 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf biolink:Publication 2019-01-01 PMID:27026201 biolink:Article Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, Hirai T, Atsumi R, Nakada T, Hayakawa I, Abe Y, Agatsuma T 2016-01-01 20 NCIT:C17998 DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 22 https://www.ema.europa.eu/en/documents/product-information/nuceiva-epar-product-information_en.pdf biolink:Publication 2019-01-01 PMID:27412122 biolink:Article Markham A 2016-01-01 12 NCIT:C17998 Atezolizumab: First Global Approval 76 PMID:30805897 biolink:Article Dhillon S 2019-01-01 5 NCIT:C17998 Roxadustat: First Global Approval 79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf biolink:Publication 2019-01-01 PMID:29856623 biolink:Article Wu Y, Jiang Z, Li Z, Gu J, You Q, Zhang X 2018-01-01 12 NCIT:C17998 Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia 61 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf biolink:Publication 2019-01-01 PMID:29061741 biolink:Article Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto S, Nakamura R, Tsuji M, Yamano Y 2017-01-01 1 NCIT:C17998 In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria 62 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209445s000lbl.pdf biolink:Publication 2019-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206488lbl.pdf biolink:Publication 2019-01-01 PMID:8103915 biolink:Article Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Sudhof TC, Niemann H, Jahn R 1993-01-01 6442 NLM:0410462 Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25 365 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214103lbl.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761150Orig1s000MultidisciplineR.pdf biolink:Publication 2020-01-01 https://www.ema.europa.eu/en/documents/assessment-report/hepcludex-epar-public-assessment-report_en.pdf biolink:Publication 2020-01-01 https://www.pmda.go.jp/files/000237990.pdf biolink:Publication 2020-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf biolink:Publication 2020-01-01 PMID:8035423 biolink:Article Rosowsky A, Bader H, Wright JE, Keyomarsi K, Matherly LH 1994-01-01 14 NCIT:C17998 Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin 37 PMID:21118657 biolink:Article Dean O, Giorlando F, Berk M 2011-01-01 2 NCIT:C17998 N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action 36 https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/18603s19lbl.pdf biolink:Publication 1998-01-01 PMID:23832378 biolink:Article Fischer F, Vonderlin N, Zitron E, Seyler C, Scherer D, Becker R, Katus HA, Scholz EP 2013-01-01 11 NCIT:C17998 Inhibition of cardiac Kv1.5 and Kv4.3 potassium channels by the class Ia anti-arrhythmic ajmaline: mode of action 386 https://www.ema.europa.eu/en/documents/mrl-report/albendazole-oxide-summary-report-2-committee-veterinary-medicinal-products_en.pdf biolink:Publication 1999-01-01 PMID:20167843 biolink:Article Doughty-Shenton D, Joseph JD, Zhang J, Pagliarini DJ, Kim Y, Lu D, Dixon JE, Casey PJ 2010-01-01 2 NCIT:C17998 Pharmacological targeting of the mitochondrial phosphatase PTPMT1 333 PMID:22981367 biolink:Article Skolnick P 2012-01-01 11 NLM:7906158 Anxioselective anxiolytics: on a quest for the Holy Grail 33 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf biolink:Publication 2021-01-01 PMID:28557445 biolink:Article Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM, Kretschmer A, Geiss V, Li V, Straub A, Mittendorf J, Jautelat R, Schirok H, Schlemmer KH, Lustig K, Gerisch M, Knorr A, Tinel H, Mondritzki T, Trubel H, Sandner P, Stasch JP 2017-01-01 12 NCIT:C17998 Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure 60 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212887s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf biolink:Publication 2021-01-01 PMID:29475723 biolink:Article Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O'Connor OA 2018-01-01 4 NCIT:C17998 Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study 19 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000PharmR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213026lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214018s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214383s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s000lbl.pdf biolink:Publication 2021-01-01 PMID:20446681 biolink:Article Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, Bur D, Gatfield J, Hess P, Kohl C, Mangold C, Mathys B, Menyhart K, Muller C, Nayler O, Scherz M, Schmidt G, Sippel V, Steiner B, Strasser D, Treiber A, Weller T 2010-01-01 10 NCIT:C17998 2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists 53 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000PharmR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211964s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761181s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf biolink:Publication 2021-01-01 PMID:18464023 biolink:Article Coelingh Bennink HJ, Holinka CF, Diczfalusy E 2008-01-01 1 NCIT:C17998 Estetrol review: profile and potential clinical applications 11 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf biolink:Publication 2021-01-01 PMID:32134960 biolink:Article Brown ME, Bedinger D, Lilov A, Rathanaswami P, Vásquez M, Durand S, Wallace-Moyer I, Zhong L, Nett JH, Burnina I, Caffry I, Lynaugh H, Sinclair M, Sun T, Bukowski J, Xu Y, Abdiche YN 2020-01-01 3 NCIT:C17998 Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors 15 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf biolink:Publication 2021-01-01 https://www.fda.gov/media/143603/download biolink:Publication 2021-01-01 https://www.fda.gov/media/145802/download biolink:Publication 2021-01-01 https://www.fda.gov/media/145611/download biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215014s000lbl.pdf biolink:Publication 2021-01-01 PMID:24497537 biolink:Article Risitano AM, Ricklin D, Huang Y, Reis ES, Chen H, Ricci P, Lin Z, Pascariello C, Raia M, Sica M, Del Vecchio L, Pane F, Lupu F, Notaro R, Resuello RR, DeAngelis RA, Lambris JD 2014-01-01 13 NLM:7603509 Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria 123 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214793s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214900s000lbl.pdf biolink:Publication 2021-01-01 PMID:24323472 biolink:Article Jimenez-Ortigosa C, Paderu P, Motyl MR, Perlin DS 2014-01-01 2 NCIT:C17998 Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates 58 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761210Orig1s000MultidisciplineR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761178Orig1s000PharmR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214429Orig1s000MultidisciplineR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214783s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215498s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215498Orig1s000IntegratedR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215383s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215383Orig1s000MultidisciplineR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215206Orig1s000lbl.pdf biolink:Publication 2021-01-01 PMID:31020659 biolink:Article Hargreaves R, Olesen J 2019-01-01 6 NLM:2985091R Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class 59 PMID:16134951 biolink:Article Huang HC, Tremont SJ, Lee LF, Keller BT, Carpenter AJ, Wang CC, Banerjee SC, Both SR, Fletcher T, Garland DJ, Huang W, Jones C, Koeller KJ, Kolodziej SA, Li J, Manning RE, Mahoney MW, Miller RE, Mischke DA, Rath NP, Reinhard EJ, Tollefson MB, Vernier WF, Wagner GM, Rapp SR, Beaudry J, Glenn K, Regina K, Schuh JR, Smith ME, Trivedi JS, Reitz DB 2005-01-01 18 NCIT:C17998 Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 2) 48 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214662s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761123s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761123Orig1s000MultidisciplineR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761177Orig1s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208Orig1s000lbledt.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761208Orig1s000MultidisciplineR.pdf biolink:Publication 2021-01-01 https://www.ema.europa.eu/en/documents/assessment-report/bimzelx-epar-public-assessment-report_en.pdf biolink:Publication 2021-01-01 https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf biolink:Publication 2021-01-01 https://www.ema.europa.eu/en/documents/product-information/klisyri-epar-product-information_en.pdf biolink:Publication 2021-01-01 PMID:31628188 biolink:Article Niu L, Yang J, Yan W, Yu Y, Zheng Y, Ye H, Chen Q, Chen L 2019-01-01 48 NLM:2985121R Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of beta-tubulin explains KXO1's low clinical toxicity 294 https://www.ema.europa.eu/en/documents/product-information/adtralza-epar-product-information_en.pdf biolink:Publication 2021-01-01 https://www.ema.europa.eu/en/documents/assessment-report/adtralza-h-c-5255-0000-epar-assessment-report_en.pdf biolink:Publication 2021-01-01 https://www.ema.europa.eu/en/documents/product-information/voxzogo-epar-product-information_en.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022454Orig1s000Lbl.pdf biolink:Publication 2021-01-01 https://www.ema.europa.eu/en/documents/assessment-report/orladeyo-epar-public-assessment-report_en.pdf biolink:Publication 2021-01-01 https://www.pmda.go.jp/files/000233074.pdf biolink:Publication 2021-01-01 PMID:25392999 biolink:Article Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U 2014-01-01 11 NCIT:C17998 Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects 9 https://www.pmda.go.jp/files/000242929.pdf biolink:Publication 2021-01-01 https://www.pmda.go.jp/files/000242410.pdf biolink:Publication 2021-01-01 PMID:33006602 biolink:Article Nishida Y, Kano K, Nobuoka Y, Seo T 2020-01-01 3 NLM:173721 Sustained-release diclofenac conjugated to hyaluronate (diclofenac etalhyaluronate) for knee osteoarthritis: a randomized phase 2 study 60 https://www.pmda.go.jp/files/000231769.pdf biolink:Publication 2019-01-01 PMID:29563324 biolink:Article Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, Kai K, Kitano Y 2018-01-01 3 NCIT:C17998 Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the alpha2delta subunit of voltage-gated calcium channels 365 PMID:30806973 biolink:Article Deeks ED 2019-01-01 4 NCIT:C17998 Mirogabalin: first global approval 79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761194s000lbl.pdf biolink:Publication 2021-01-01 PMID:34390486 biolink:Article Hoy SM 2021-01-01 13 NCIT:C17998 Upacicalcet: first approval 81 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214985s000lbl.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214487Orig1s000MultidisciplineR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig2lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215358Orig1s000,Orig2s000MultidisciplineR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215596lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214907s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761195Orig1s000IntegratedR.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761195s000lbl.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761224s000lbl.pdf biolink:Publication 2021-01-01 https://www.ema.europa.eu/en/documents/product-information/regkirona-epar-product-information_en.pdf biolink:Publication 2021-01-01 PMID:33436577 biolink:Article Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim YG, Jeong JH, Kim M, Kim JI, Kim P, Bae JS, Shim EY, Lee MS, Kim MS, Noh H, Park GS, Park JS, Son D, An Y, Lee JN, Kwon KS, Lee JY, Lee H, Yang JS, Kim KC, Kim SS, Woo HM, Kim JW, Park MS, Yu KM, Kim SM, Kim EH, Park SJ, Jeong ST, Yu CH, Song Y, Gu SH, Oh H, Koo BS, Hong JJ, Ryu CM, Park WB, Oh MD, Choi YK, Lee SY 2021-01-01 1 NLM:101528555 A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein 12 PMID:27189825 biolink:Article Hanifin JM, Ellis CN, Frieden IJ, Folster-Holst R, Stein Gold LF, Secci A, Smith AJ, Zhao C, Kornyeyeva E, Eichenfield LF 2016-01-01 2 NCIT:C17998 OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study 75 PMID:34807428 biolink:Article Deeks ED, Duggan S 2021-01-01 18 NCIT:C17998 Abrocitinib: first approval 81 PMID:29298069 biolink:Article Vazquez ML, Kaila N, Strohbach JW, Trzupek JD, Brown MF, Flanagan ME, Mitton-Fry MJ, Johnson TA, TenBrink RE, Arnold EP, Basak A, Heasley SE, Kwon S, Langille J, Parikh MD, Griffin SH, Casavant JM, Duclos BA, Fenwick AE, Harris TM, Han S, Caspers N, Dowty ME, Yang X, Banker ME, Hegen M, Symanowicz PT, Li L, Wang L, Lin TH, Jussif J, Clark JD, Telliez JB, Robinson RP, Unwalla R 2018-01-01 3 NCIT:C17998 Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d] pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases 61 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209607s000lbl.pdf biolink:Publication 2018-01-01 https://www.ema.europa.eu/en/documents/product-information/xevudy-epar-product-information_en.pdf biolink:Publication 2021-01-01 https://www.pmda.go.jp/files/000245006.pdf biolink:Publication 2021-01-01 https://www.ema.europa.eu/en/documents/product-information/sugammadex-mylan-epar-product-information_en.pdf biolink:Publication 2021-01-01 https://www.ema.europa.eu/en/documents/product-information/vumerity-epar-product-information_en.pdf biolink:Publication 2021-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216196s000lbl.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/208712Orig1s000IntegratedR.pdf biolink:Publication 2022-01-01 PMID:9067315 biolink:Article Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, White HS, Wolf HH, Mirsadeghi S, Tahir SH, Bolger MB, Lan NC, Gee KW 1997-01-01 3 NCIT:C17998 Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid A receptor 280 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215833Orig1s000MultidisciplineR.pdf biolink:Publication 2022-01-01 PMID:25224009 biolink:Article Warrilow AG, Hull CM, Parker JE, Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Kelly DE, Kelly SL 2014-01-01 12 NCIT:C17998 The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme 58 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214998s000lbl.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761164s000lbl.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761164Orig1s000PharmR.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761228Orig1s000MultidisciplineR.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761228s000lbl.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761234Orig1s000MultidisciplineR.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761235Orig1s000PharmR.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf biolink:Publication 2022-01-01 PMID:30473097 biolink:Article Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A 2018-01-01 NCIT:C17998 LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept 18 https://www.ema.europa.eu/en/documents/product-information/ngenla-epar-product-information_en.pdf biolink:Publication 2022-01-01 PMID:26713839 biolink:Article Hershkovitz O, Bar-Ilan A, Guy R, Felikman Y, Moschcovich L, Hwa L, Rosenfeld RG, Fima E, Hart G 2016-01-01 2 NCIT:C17998 In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone 13 PMID:33613288 biolink:Article Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, Clozel JP, Clozel M 1997-01-01 3 NCIT:C17998 Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm 283 PMID:35347635 biolink:Article Markham A 2022-01-01 6 NCIT:C17998 Gefapixant: first approval 82 PMID:35465163 biolink:Article Cui WW, Wang SY, Zhang YQ, Wang Y, Fan YZ, Guo CR, Li XH, Lei YT, Wang WH, Yang XN, Hattori M, Li CZ, Wang J, Yu Y 2022-01-01 NCIT:C17998 P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough 20 https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf biolink:Publication 2022-01-01 PMID:35305258 biolink:Article Lamb YN 2022-01-01 5 NCIT:C17998 Nirmatrelvir plus ritonavir: first approval 82 https://www.ema.europa.eu/en/documents/product-information/tavneos-epar-product-information_en.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000PharmR.pdf biolink:Publication 2022-01-01 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf biolink:Publication 2022-01-01 PMID:28595996 biolink:Article Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, Coquery CM, Neil J, Pryor WM, Mayhew D, Rajpal DK, Creech K, Furst S, Lee J, Wu D, Rastinejad F, Willson TM, Viviani F, Morris DC, Moore JT, Cote-Sierra J 2017-01-01 10 NCIT:C17998 Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans 137 PMID:34991690 biolink:Article Wei M, Zhang X, Pan X, Wang B, Ji C, Qi Y, Zhang JZH 2022-01-01 1 NLM:101516718 HobPre: accurate prediction of human oral bioavailability for small molecules 14 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761181Orig1s000PharmR.pdf biolink:Publication 2021-01-01